Check for updates

OPEN ACCESS

EDITED BY Vahid Serpooshan, Emory University, United States

REVIEWED BY

Martin Mueller, University Hospital Bern, Switzerland Moein Zangiabadian, Shahid Beheshti University of Medical Sciences, Iran

*CORRESPONDENCE Junsong Ye, ⊠ yjs1211@163.com

SPECIALTY SECTION

This article was submitted to Tissue Engineering and Regenerative Medicine, a section of the journal Frontiers in Bioengineering and Biotechnology

RECEIVED 29 July 2022 ACCEPTED 30 November 2022 PUBLISHED 14 December 2022

CITATION

Qu J, Zhou L, Zhang H, Han D, Luo Y, Chen J, Li L, Zou Z, He Z, Zhang M and Ye J (2022), Efficacy and safety of stem cell therapy in cerebral palsy: A systematic review and meta-analysis. *Front. Bioeng. Biotechnol.* 10:1006845. doi: 10.3389/fbioe.2022.1006845

COPYRIGHT

© 2022 Qu, Zhou, Zhang, Han, Luo, Chen, Li, Zou, He, Zhang and Ye. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Efficacy and safety of stem cell therapy in cerebral palsy: A systematic review and meta-analysis

Jiayang Qu^{1,2,3}, Lin Zhou¹, Hao Zhang³, Dongmiao Han², Yaolin Luo^{1,4}, Junming Chen^{1,2}, Lincai Li¹, Zhengwei Zou¹, Zhengyi He^{1,4}, Minhong Zhang^{1,4} and Junsong Ye^{1.5,6,7}*

¹Subcenter for Stem Cell Clinical Translation, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China, ²School of Rehabilitation Medicine Gannan Medical University, GanZhou City, Jiangxi, China, ³The First Clinical College of Gannan Medical University, Ganzhou, Jiangxi, China, ⁴Clinical Medicine Research Center, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China, ⁵Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Gannan Medical University, Ganzhou, Jiangxi, China, ⁶Key Laboratory of Biomaterials and Biofabrication in Tissue Engineering of Jiangxi Province, Gannan Medical University, Ganzhou, Jiangxi, China, ⁷Ganzhou Key Laboratory of Stem Cell and Regenerative Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China

Aim: Although the efficacy and safety of stem cell therapy for cerebral palsy has been demonstrated in previous studies, the number of studies is limited and the treatment protocols of these studies lack consistency. Therefore, we included all relevant studies to date to explore factors that might influence the effectiveness of treatment based on the determination of safety and efficacy.

Methods: The data source includes PubMed/Medline, Web of Science, EMBASE, Cochrane Library, from inception to 2 January 2022. Literature was screened according to the PICOS principle, followed by literature quality evaluation to assess the risk of bias. Finally, the outcome indicators of each study were extracted for combined analysis.

Results: 9 studies were included in the current analysis. The results of the pooled analysis showed that the improvements in both primary and secondary indicators except for Bayley Scales of Infant and Toddler Development were more skewed towards stem cell therapy than the control group. In the subgroup analysis, the results showed that stem cell therapy significantly increased Gross Motor Function Measure (GMFM) scores of 3, 6, and 12 months. Besides, improvements in GMFM scores were more skewed toward umbilical cord mesenchymal stem cells, low dose, and intrathecal injection. Importantly, there was no significant difference in the adverse events (RR = 1.13; 95% CI = [0.90, 1.42]) between the stem cell group and the control group.

Conclusion: The results suggested that stem cell therapy for cerebral palsy was safe and effective. Although the subgroup analysis results presented guiding significance in the selection of clinical protocols for stem cell therapy, high-quality RCTs validations are still needed.

KEYWORDS cerebral palsy, stem cell therapy, meta-analysis, efficacy, safety

1 Introduction

Cerebral palsy (CP) was first described as cerebral paresis by Little in 1861 (Little, 1861). The appropriate definition of CP is difficult owing to the heterogeneity of the diseases (Colver et al., 2014). In 2005, CP has been defined as a group of disorders of the development of movement and posture that cause activity limitation by the Executive Committee for the Definition of CP (Bax et al., 20052005). Specifically, CP is attributed to a non-progressive disturbance that occurred in the developing fetal or infant brain (Chin et al., 2022). The phenotypic motor disorders of CP are often accompanied by disturbances of sensation (Greene, 2021), cognition (Stadskleiv, 2020), communication (Mei et al., 2020), perception (Aisen et al., 2011) and epilepsy (El Tantawi et al., 2019), which generates great pain to both the patient and the family. The pooled overall prevalence of CP was 2.11 per 1,000 live births (Oskoui et al., 2013) all over the world, and the pooled prevalence of CP over the 32 years from 1988 to 2020 was 2.07‰ in China (Yang et al., 2021). Meanwhile, CP exerted higher prevalence in low- and middle-income countries than that in high-income countries. For example, the objective observed prevalence was 3.4 per 1,000 children in Bangladesh (Khandaker et al., 2019).

Currently, it still remains unclear whether the medical drugs, surgery or rehabilitation means merely aiming to reduce secondary musculoskeletal deformity in CP, rather than treat the primary central neurological deficit (Colver et al., 2014). Whereas, compared with traditional chemical drugs, stem cells as "drugs" are characterized by nontargeting, multi-potential and flexible function, which makes them have the potential to treat complicated diseases. For example, stem cells have several functions that might be critical to the treatment of CP including immune regulation (Bennet et al., 2012), paracrine effects (Lv et al., 2021), angiogenesis (Kiasatdolatabadi et al., 2017), and neuroplasticity (Jantzie et al., 2018). Collectively, stem cell transplantation is considered a promising therapeutic strategy in clinical practice (Xie et al., 2020), and the effectiveness of stem cell transplantation in the treatment of CP has been preliminarily verified by evidence-based medicine (Novak et al., 2016; Eggenberger et al., 2019; Xie et al., 2020; Smith et al., 2021). However, we found that stem cell treatment protocols were non-uniform across studies, and previous systematic reviews did not provide appropriate recommendations on factors that may affect the therapeutic effect, such as cell type selection, dose and administration. Herein, we aim to rigorously screen and extract all clinical trial data on stem cell therapy (SCT) for CP, and objectively

evaluate and summarize evidence of SCT for CP symptoms through systematic review and meta-analysis. In addition, based on the results of subgroup analysis, we also provide suggestions for the selection of treatment options, in order to promote the clinical application of SCT in CP.

2 Methods

The detailed protocol is registered in the PROSPERO (CRD42022301070, https://www.crd.york.ac.uk/PROSPERO/). The preferred reporting checklist (PRISMA) of systematic reviews and meta-analysis were used to guide this study (Supplementary Material S1).

2.1 Inclusion criteria

1). Population: patients diagnosed with CP, regardless of region, gender or race; 2). Intervention: stem cells therapy in combination with or without other treatments; 3). Comparisons: rehabilitation therapy and regular medication; d). Outcomes: the indicators are the scores of Gross Motor Function Measure (GMFM), Comprehensive Function Assessment (CFA), Gross Motor Performance Measure (GMPM), Bayley Scales of Infant and Toddler Development (BSID-II) and Functional Independence Measure for Children (WeeFIM) or any other evaluation tools suitable for CP; e). Study Types: Randomized Controlled Trials (RCTs) that paralleled or crossover.

2.2 Exclusion criteria

Reports, reviews, abstracts, trials and letters with duplicate, incomplete and unavailable data were excluded. In addition, studies that are not relevant to the topic of this paper (such as studies using animal models or *in vitro* models as experimental subjects and using interventions that are not stem cell transfusions) are excluded.

2.3 Data sources

The following English databases were searched from the inceptions to 2 January 2022: PubMed/Medline, Web of Science, EMBASE, Cochrane library. The MeSH and keywords search terms included Stem Cells, Progenitor Cells, Mother Cells, CP, Dystonic-Rigid and Cerebral Palsies. A detailed illustration of search strategies is available in Supplementary Material S2.

2.4 Data extraction and quality assessment

Two independent reviewers evaluated the retrieved studies for inclusion and assessed the methodological quality of included studies. Elements extracted included study characteristics (author, country, publication year and design), participant characteristics (sex, age range and diagnostic criteria), intervention details (types of cells, dose ranges, administration and frequency), outcome measures, and follow-up time. The risk of bias was assessed using ROB2 (Risk of bias tool 2) (Higgins et al., 2011). The disagreements were thrashed out by the additional reviewer.

2.5 Data analysis

Data entry and analysis were performed using Review Manager 5.3 software. The data required for meta-analysis was directly extracted from the original literature or indirectly calculated on the basis of the original data through the conversion tool (https://www.yxzlb.com/forum.php?mod= viewthread&tid=3679&page=1#pid9919) developed bv Chinese scholars (For example, SE of GMFM in study Kang et al. (2015) needs to be converted into standard deviation (SD), and SD of GMFM in study (Rah et al., 2017) needs to be calculated by p-value and sample size.). Since CFA, GMPM and WeeFIM were used uniformly in various studies, the fixed-effect model and its index WMD were used in their combined analysis. The random effects model and its indicator, SMD, were used in the combined analysis of GMFM and BSID-II because the different versions of these scales used in the included studies resulted in large differences in the means. The weighted mean difference (WMD) and standardized mean difference (SMD) were used to compare continuous variables (GMFM, CFA, BSID-II and GMPM), while risk ratio (RR) was used to compare binary variables (Adverse events). All results obtained were reported with 95% confidence intervals (CI). Heterogeneity among studies was determined by Q test and I² statistics [Cochrane book 9.5. 2 Identifying and measuring heterogeneity, 0%-40%:might not be important; 30%-60%: may represent moderate heterogeneity*; 50%-90%: may represent substantial heterogeneity*; 75%-100%: considerable heterogeneity* (Cumpston et al., 2019)]. With substantial heterogeneity, sensitivity analysis or subgroup analysis was used to detect the source of heterogeneity; if the source of heterogeneity cannot be found, a descriptive analysis was conducted. Meanwhile, funnel plots were used to assess publication bias. For trials that had a crossover design, we included all the data before and after the crossover. When studies of multiple intervention groups are compared, the "shared" control group is split equally in each comparison.

3 Results

3.1 Results of the search


A flowchart describing the selection of eligible trials is presented in Figure 1. A total of 798 articles from 4 databases were retrieved: Web of Science (n = 139) databases, PubMed/ MEDLINE (n = 107), Cochrane (n = 141), Embase (n = 411). Studies (n = 23) from previously published reviews (Kułak-Bejda et al., 2016; Novak et al., 2016; Eggenberger et al., 2019; Xie et al., 2020) were also included for screening. After reexamination and other screening, 35 studies were included. However, 15 of the studies were clinical registration trials with no outcome, 6 of the conference abstracts without full text and relevant data, and 5 of the studies were duplicated with data from other literatures. Finally, 9 studies were included in our meta-analysis.

3.2 Characteristics of the studies

The characteristics of the included studies are listed in Table 1. Two studies recruited patients from Iran and America respectively. Four of the remaining seven studies came from China and three from South Korea. Except for Huang et al. (2018) was single-blind RCT and Luan et al. (2012) did not report blindness, the rest were double-blind RCT designs, among which Sun et al. (2017) and Rah et al. (2017) were crossover designs study Liu et al. (2017) conducted simultaneous interventions of two stem cell types, bone marrow mesenchymal stem cell (BMMSC) and bone marrow mononuclear cell (BMMNC) on CP. Therefore, we divided them into two groups for data extraction.Amanat et al. (2021) and Liu et al. (2017) included only patients with spastic CP in their studies. All the studies' sample sizes ranged from 36 to 105 and were published from 2012 to 2021. The main transfused routes are intravenous infusion and intrathecal injection, which total dose ranged from 4 \times $10^6 - 5.2 \times 10^8 / \text{kg.}$

3.3 Risk assessment of bias

Figure 2 showed the assessment results of bias risk and methodological suitability of the included studies. As all the 9 included studies were RCTs, the bias arising from the randomisation process was low risk. Only three studies used appropriate analyses to estimate the effect of assignment to intervention. In addition, Huang et al. (2018) was a single-blind design and Luan et al. (2012) was a nonblind design, which makes carers and people delivering the interventions aware of the participants' assigned intervention during the trial. Therefore, bias due to deviations from intended intervention of 6 studies are considered some



concerns. Bias due to missing outcome date was high risk in Rah et al. (2017), as the availability of date small than 95%. Huang et al. (2018) and Luan et al. (2012)'s bias in measurement of the outcome was high risk due to the implementation of the inappropriate blind method mentioned above. Besides, Gu et al. (2020) and Rah et al. (2017)'s clinical trial registration status was retrospectively registration, and Huang et al. (2018) and Luan et al. (2012) did not provide information on clinical registration. We believe that their bias in selection of the reported result were some concerns. Detailed results of the ROB2 assessment are provided in Supplementary Material S3.

3.4 Meta-analysis

Nine eligible articles were meta-analyzed using a random effects model, with GMFM as primary and CFA, GMPM, BSID-II, WeeFIM as secondary indicators to evaluate the effectiveness of SCT for CP, and adverse events (AE) as a safety indicator.


3.4.1 Primary indicators

GMFM scores were reported in 9 studies of 317 patients with SCT and 329 patients in the control group. We found that although every article used the GMFM score as one of the outcome indicators, some articles used GMFM-88 while

TABLE 1 Summary of Clinical Studies of Stem Cells Therapy for cerebral palsy.

Study Country Design										Patient condition		Ther	ару			Con	trol		Follow up	Main outcome
			Sample size	Average age, y	Cell type	Dose	Administration	Sample size	Average age, y	Control intervention		measures								
Amanat et al. (2021)	Iran	RCT double- blind	72	4-14	spastic CP, GMFCS level 2–5, white matter lesions	36	8.475	hUC- MSC	2 × 10 ⁷ /kg, single time	intrathecal route	36	8.542	sham procedure, Bobath therapy	1, 3, 6, and 12-month	GMFM-66, MAS, PEDI, C QoL, FA and MD of CST and PTR.					
Gu et al. (2020)	China	RCT double- blind	40	2-12	CP	20	3.83	hUC- MSC	4.5–5.5 × 10 ⁷ /kg, 50ml, 4 times	intravenous infusion	20	4.775	Placebo, Bobath therapy and conductive education	12-month	GMFM-88, ADL, CFA, ¹⁸ F-FDG- PET/CT					
Huang et al. (2018)	China	RCT single- blind	54	3-12	СР	27	7.3	hUCB- MSC	5× 10 ⁷ /kg, 4 times	intravenous infusions	27	7.5	normal saline, basic rehabilitation	3, 6, 12, 24- month	GMFM-88, CF Lab test, EEG, MRI					
Kang et al. (2015)	Korea	RCT double- blind	36	0.5–15	CP	18	3.9	UCB	5.46× 10 ⁷ /kg	intravenous or intra- arterial routes	18	3.775	placebo	2-week and 1, 3, 6- month	MMT, GMFM GMPM, BSID- WeeFIM [®] , PEI 18F-FDG-PET					
Liu et al. (2017)	China	RCT double- blind	105	0.5-12.5	spastic CP	35	4.129	A: BMMSC	1×10^6 /kg, four times	intrathecal injections	35	4.105	Bobath therapy	3, 6, and 12- month	GMFM, FMFM					
						35	4.092	B: BMMNC												
Luan et al. (2012)	China	RCT	94	0.4-3.3	СР	49	1.083	NPCs	8-10 × 10 ⁶ , 200 μL	lateral ventricles	45	1.569	rehabilitation training	1 year	GMFM, PDMS Survey questionnaire					
Min et al. (2013)	Korea	RCT double- blind	96	0.5-7.3	CP	31	3.067	UCB + RhEPO	TNCs ≥3 × 10 ⁷ /kg	intravenous infusion	32	3.192	rehabilitation training	1, 3, 6- month	GMPM, BSID- Mental and Motor scales, GMFM, WeeFIM, 18F- FDG-PET/CT					
Rah et al. (2017)	Korea	RCT double- blind, crossover	47	2-10	CP	47	4.1	mPBMC	5.2×10^8 /kg	intravenous infusion	47	4.1	personalized physiotherapy and occupational therapies	6-month	GMFM, PEDI, Quest					
Sun et al. (2017)	America	RCT double- blind	63	1-6	СР	32	2.1	ACB	1-5×10 ⁷ /kg	intravenous infusion	31	2.3	placebo, traditional rehabilitation therapies	1,2-year	PDMS-2, GMFM-66					

Gross motor function measure (GMFM), modified Ashworth scale (MAS), pediatric evaluation of disability inventory (PEDI), CP quality of life (CP-QoL), fractional anisotropy (FA), Comprehensive Function Assessment (CFA), Gross Motor Performance Measure (GMPM), Functional Independence Measure for Children (WeeFIM), Bayley Scales of Infant and Toddler Development (BSID-II), mean diffusivity (MD), corticospinal tract (CST), posterior thalamic radiation (PTR), human umbilical cord mesenchymal stem cells (hUC-MSC), human umbilical cord blood mesenchymal stem cells (hUC-MSC), human umbilical cord blood mesenchymal stem cells (hUCB-MSC), umbilical cord blood (UCB), Bone marrow mesenchymal stem cells (BMMSCs), bone marrow mononuclear cells (BMMNCs), neural progenitor cells (NPCs), Peabody Developmental Motor Scale-Fine Motor (PDMS-FM), recombinant human erythropoietin (rhEPO), Quality of Upper Extremity Skills Test (QUEST), Manual Ability Classification System (MACS), autologous cord blood (ACB), total nucleated cell (TNC)



others used GMFM-66, which is a simplified version of the former, leading to a huge difference in the mean value. So SMD was selected as the effect indicator. Data showed that the GMFM score of the stem cell group was significantly higher than the control group (SMD: 0.63; 95% CI [0.22, 1.03]; p = 0.002) (Figure 3A). A higher score of GMFM refers to the lighter symptoms. However, heterogeneity test p < 0.00001; $I^2 = 82\%$, indicating considerable heterogeneity. Sensitivity analysis suggested that Huang et al. (2018) and might be the source of heterogeneity, when they were removed, the results showed that the heterogeneity was greatly reduced (p = 0.39; $I^2 =$ 5%) and the results were more stable (SMD: 0.49; 95% CI [0.30, 0.69]; p < 0.00001) (Figure 3B). Before sensitivity analysis, funnel plot corresponding to forest map showed skewness distribution. After sensitivity analysis, the source of heterogeneity was removed and the funnel plot was normally distributed (Supplementary Material S4).

3.4.2 Secondary indicators

CFA scores were reported in 2 studies of 46 patients with SCT and 47 patients in the control group. From the meta-analysis (Figure 4A), stem cells greatly improved performance compared with controls on the CFA (WMD: 14.17; 95% CI: 11.52, 16.81; p < 0.00001; Heterogeneity test I² = 0%, p = 0.50).

Our systematic literature review identified 2 studies (n = 87 participants) that investigated the effectiveness of SCT on GMPM in children with CP. Pooled analysis indicated that SCT significantly improved GMPM scores (WMD = 5.74, 95% CI = 3.89–7.59, p < 0.00001; Heterogeneity test I² = 0%, p = 0.67) (Figure 4B), compared with the control group.

Two studies (Min et al., 2013; Kang et al., 2015) collected WeeFIM outcome data. Pooled analysis showed that the WeeFIM score of the stem cell group was significantly higher than the control group (WMD: 0.88; 95% CI [0.19, 1.57]; p = 0.01; Heterogeneity test I² = 0%, p = 0.97) (Figure 4C).

٨					Question			Old Mary Difference	Old Man Difference
A		perimental		Man	Control	Tatel	M/+1+1+1	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	STATE INCOME.	1000 B 1000	Mean		Total		a second second second second second	IV, Random, 95% Cl
Amanat 2021	10.65	15.55	36	1.23	13.49	36	10.6%		
Gu 2020	64.526	41.85	19	36.8	8.802	20	9.3%		
Huang 2018	12.66	3.429	27	4.81	2.026	27	8.6%	2.75 [1.99, 3.50]	
Kang 2015	7.08	8.441	13	3.85	3.752	17	8.8%	0.51 [-0.23, 1.24]	
Liu 2017a		34.35075	33		28.75533	17	9.7%	0.74 [0.14, 1.35]	
Liu 2017b		31.24451	34		28.75533	18	9.9%		
Luan 2012	5.69	2.91	45	3.92	2.33	49	11.0%		
Min 2013	9.1	6.681	31	7.8	5.091	32	10.5%		
Rah 2017	0.3725	0.188	47	0.4	0.188	47	11.0%		
Sun 2017	7.5	6.8	32	6.9	5.5	31	10.5%	0.10 [-0.40, 0.59]	
Total (95% CI)			317			294	100.0%	0.63 [0.22, 1.03]	◆
Heterogeneity: Tau ² =	0.34; Chi	² = 50.92, d	f = 9 (F	o < 0.00	001); l ² = 82	2%		_	-2 -1 0 1 2
Test for overall effect:	Z = 3.04	(P = 0.002)							Favours [control] Favours [experimental
Р	-							0.1 M D'''	
B		perimental			Control	T - 4 - 1	14/-1-1-4	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean			Mean			Weight		IV, Random, 95% CI
Amanat 2021	10.65	15.55	36	1.23	13.49	36	15.6%		
Gu 2020	64.526	41.85	19	36.8	8.802	20	8.2%		
Huang 2018	12.66	3.429	27	4.81	2.026	27	0.0%		
Kang 2015	7.08	8.441	13	3.85	3.752	17	6.8%		
Liu 2017a		34.35075	33		28.75533	17	9.9%		
Liu 2017b		31.24451	34		28.75533	18	10.9%		T
Luan 2012	5.69	2.91	45	3.92	2.33	49	19.9%		
Min 2013	9.1	6.681	31	7.8	5.091	32	14.4%		
Rah 2017	0.3725	0.188	47	0.4	0.188	47	0.0%		
Sun 2017	7.5	6.8	32	6.9	5.5	31	14.4%	0.10 [-0.40, 0.59]	
Total (95% CI)			243			220	100.0%	0.49 [0.30, 0.69]	•
Heterogeneity: Tau ² =	0.00; Chi	² = 7.38, df	= 7 (P	= 0.39);	l² = 5%			-	-2 -1 0 1 2
Test for overall effect:	Z = 4.97	(P < 0.0000	1)						Favours [control] Favours [experimental
FIGURE 3									
Primary indicators.	Forest plo	ot of GMFM	1. (A) P	ooled r	results befo	ore sen	sitivity ar	nalysis. (B) Pooled results	after eliminating heterogeneous
sources.									

In the two studies (Min et al., 2013; Kang et al., 2015), BSID-II scores were reported as mental scale and motor scale, so we also conducted a subgroup analysis of the results of BSID-II (Figure 4D). Regrettably, there was no difference in either mental scale (WMD = 0.38, 95% CI = -0.50–1.26, p = 0.40; Heterogeneity test I² = 76%, p = 0.04) or motor scale (WMD = 0.43, 95% CI = -0.27–1.12, p = 0.23; Heterogeneity test I² = 63%, p = 0.10) scores between the stem cell treatment group and the control group. However, it is worth noting that the heterogeneity in the pooling of the two parts of the scale is greatly high.

3.4.3 Subgroup of gross motor function measure 3.4.3.1 Time subgroup of gross motor function measure

At the same time as the treatment follow-up endpoint data were extracted, the follow-up node data for each study were also extracted. We performed the time subgroup analysis for GMFM, pooled analysis showed that SCT significantly increased GMFM scores (SMD = 0.35, 95%CI = [021, 0.50], p < 0.00,001, heterogeneity test p = 0.06; $I^2 = 35\%$) (Figure 5), compared with the control group. Subgroup analysis with random-effects model showed that SCT significantly increased GMFM scores in

3 months (SMD: 0.27; 95%CI [0.04, 0.49]; p = 0.02), 6 months (SMD: 0.51; 95%CI [0.27, 0.74]; p < 0.0001; heterogeneity test p = 0.41; I² = 2%), and 12 months (SMD: 0.54; 95%CI [0.31, 0.77]; p < 0.00001; heterogeneity test p = 0.31; I² = 17%.). Whereas, comparisons between the two groups showed no difference in 1 month (SMD = -0.06, 95%CI = -0.39-0.27, p = 0.71; heterogeneity test p = 0.23; I² = 30%).

3.4.3.2 Stem cells type subgroup of gross motor function measure

To determine the optimal cell type for SCT in CP, we conducted a subgroup analysis of the two main cell types included in the studies (Figure 6A). Data showed that the GMFM score of the treatment group was significantly higher than the control group in MSC group (SMD: 0.73; 95%CI [0.41, 1.06]; p < 0.00001; heterogeneity test p = 0.81; $I^2 = 0\%$) (Figure 6A). In contrast, the GMFM score of the treatment group showed no difference with control group in UCB group (SMD: 0.22; 95%CI [-0.10, 0.54]; p = 0.17; heterogeneity test p = 0.66; $I^2 = 0\%$). There was significant heterogeneity between the two cell types (heterogeneity test p = 0.03; $I^2 = 79.7\%$).

A		erimenta			Control			Mean Difference	Mean Difference
Study or Subgroup	Mean		Total	Mean			Weight		IV, Fixed, 95% Cl
Gu 2020	25.737 25	17.205 6.391			16.927		6.1%	10.56 [-0.16, 21.28]	
Huang 2018	25	6.391	27	10.6	3.377	27	93.9%	14.40 [11.67, 17.13]	-
Total (95% CI)			46			47	100.0%	14.17 [11.52, 16.81]	•
Heterogeneity: Chi ² = 0	and accordent to the		/.	= 0%					-20 -10 0 10 20
Test for overall effect:	Z = 10.51	(P < 0.0	0001)						Favours [control] Favours [experiment
3	Exp	erimen	tal		Control			Mean Difference	Mean Difference
Study or Subgroup				Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Kang 2015	8.54	2.14	8	2.6	2.92	16	80.9%	5.94 [3.88, 8.00]	
Min 2013	14.5	10.022	31	9.6	6.788	32	19.1%	4.90 [0.66, 9.14]	
Total (95% CI)			39			48	100.0%	5.74 [3.89, 7.59]	
Heterogeneity: Chi ² =	0 19 df :	= 1 (P =		² = 0%		40	100.070		+ + + · · ·
Test for overall effect:				- 0 /0					-10 -5 0 5 10 Favours [control] Favours [experimer
c	_								
C		eriment			Control	Tetel		Mean Difference	Mean Difference
Study or Subgroup				Mean			-	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Kang 2015 Min 2013	1.59	3.175	17 31		5.566	17	5.1%	0.47 [-2.58, 3.52]	
WIII 2013	1.5	1.67	31	0.4	1.131	32	94.9%	0.90 [0.19, 1.61]	
Total (95% CI)			48			49	100.0%	0.88 [0.19, 1.57]	◆
Total (95% CI) Heterogeneity: Chi ² =	• 0.07, df	= 1 (P =		l² = 0%		49	100.0%	0.88 [0.19, 1.57]	
,			0.79);	l² = 0%		49	100.0%	0.88 [0.19, 1.57] -	-2 -1 0 1 2 Favours [control] Favours [experiment
Heterogeneity: Chi ² = Test for overall effect	: Z = 2.50) (P = 0.	0.79); 01)			49		-	Favours [control] Favours [experiment
Heterogeneity: Chi ² = Test for overall effect D	: Z = 2.50 Expe) (P = 0.) erimenta	0.79); 01)	С	ontrol		SI	d. Mean Difference	Favours [control] Favours [experimen Std. Mean Difference
Heterogeneity: Chi ² = Test for overall effect	: Z = 2.50) (P = 0.) erimenta	0.79); 01)	С	ontrol		SI	-	Favours [control] Favours [experimen Std. Mean Difference
Heterogeneity: Chi ² = Test for overall effect D Study or Subgroup	: Z = 2.50 Expe) (P = 0.) erimenta	0.79); 01)	С	ontrol SD	Total V	SI	d. Mean Difference	Favours [control] Favours [experimen Std. Mean Difference
Heterogeneity: Chi ² = Test for overall effect D Study or Subgroup 2.1.1 Mental scale	: Z = 2.50 Expe Mean 8.94) (P = 0.) erimenta SD	0.79); 01) II Total	C <u>Mean</u> 9.82	ontrol SD	Total V	St Veight	d. Mean Difference IV. Random. 95% CI	Favours [control] Favours [experimen Std. Mean Difference
Heterogeneity: Chi ² = Test for overall effect D Study or Subgroup 2.1.1 Mental scale Kang 2015	: Z = 2.50 Expe Mean 8.94) (P = 0.1 erimenta <u>SD</u> 8.24	0.79); 01) II <u>Total</u> 16	C <u>Mean</u> 9.82	ontrol SD 8.535	Total V	Si <u>Veight</u> 21.9%	d. Mean Difference <u>IV. Random. 95% CI</u> -0.10 [-0.79, 0.58]	Favours [control] Favours [experimen Std. Mean Difference
Heterogeneity: Chi ² = Test for overall effect D Study or Subgroup 2.1.1 Mental scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² =	: Z = 2.50 Expe Mean 8.94 17.6 0.31; Chi	erimenta SD 8.24 10.022 2 = 4.25,	0.79); 01) II <u>Total</u> 16 31 47 df = 1	C <u>Mean</u> 9.82 9.9	ontrol SD 8.535 9.051	Total V 17 32 49	St <u>Veight</u> 21.9% 28.1%	td. Mean Difference <u>IV. Random. 95% CI</u> -0.10 [-0.79, 0.58] 0.80 [0.28, 1.31]	Favours [control] Favours [experimen Std. Mean Difference
Heterogeneity: Chi ² = Test for overall effect D Study or Subgroup 2.1.1 Mental scale Kang 2015 Min 2013 Subtotal (95% CI)	: Z = 2.50 Expe Mean 8.94 17.6 0.31; Chi	erimenta SD 8.24 10.022 2 = 4.25,	0.79); 01) II <u>Total</u> 16 31 47 df = 1	C <u>Mean</u> 9.82 9.9	ontrol SD 8.535 9.051	Total V 17 32 49	St <u>Veight</u> 21.9% 28.1%	td. Mean Difference <u>IV. Random. 95% CI</u> -0.10 [-0.79, 0.58] 0.80 [0.28, 1.31]	Favours [control] Favours [experimen Std. Mean Difference
Heterogeneity: Chi ² = Test for overall effect D Study or Subgroup 2.1.1 Mental scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² =	: Z = 2.50 Expe Mean 8.94 17.6 0.31; Chi	erimenta SD 8.24 10.022 2 = 4.25,	0.79); 01) II <u>Total</u> 16 31 47 df = 1	C <u>Mean</u> 9.82 9.9	ontrol SD 8.535 9.051	Total V 17 32 49	St <u>Veight</u> 21.9% 28.1%	td. Mean Difference <u>IV. Random. 95% CI</u> -0.10 [-0.79, 0.58] 0.80 [0.28, 1.31]	Favours [control] Favours [experimen Std. Mean Difference
Heterogeneity: Chi ² = Test for overall effect D 2.1.1 Mental scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect:	: Z = 2.50 Expe Mean 8.94 17.6 0.31; Chi	erimenta SD 8.24 10.022 2 = 4.25,	0.79); 01) II <u>Total</u> 16 31 47 df = 1	C <u>Mean</u> 9.82 9.9	ontrol SD 8.535 9.051 4); I ² = 7	Total V 17 32 49 76%	St <u>Veight</u> 21.9% 28.1%	td. Mean Difference <u>IV. Random. 95% CI</u> -0.10 [-0.79, 0.58] 0.80 [0.28, 1.31]	Favours [control] Favours [experimen Std. Mean Difference
Heterogeneity: Chi ² = Test for overall effect D 2.1.1 Mental scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 2.1.2 Motor scale Kang 2015 Min 2013	: Z = 2.50 Expe Mean 8.94 17.6 0.31; Chi Z = 0.84 3.25	 P = 0.0 P = 0.0 P = 0.0 P = 0.1 SD 8.24 10.022 2 = 4.25, (P = 0.40 	0.79); 01) II Total 16 31 47 df = 1 0) 16 31	C 9.82 9.9 (P = 0.0 3.12	ontrol SD 8.535 9.051 4); I ² = 7	Total V 17 32 49 76% 17 32	St <u>Veight</u> 21.9% 28.1% 49.9% 21.9% 28.2%	 Id. Mean Difference IV. Random, 95% CI -0.10 [-0.79, 0.58] 0.80 [0.28, 1.31] 0.38 [-0.50, 1.26] 0.03 [-0.65, 0.71] 0.75 [0.23, 1.26] 	Favours [control] Favours [experimen Std. Mean Difference
Heterogeneity: Chi ² = Test for overall effect D 2.1.1 Mental scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 2.1.2 Motor scale Kang 2015 Min 2013 Subtotal (95% Cl)	: Z = 2.50 Expe Mean 8.94 17.6 0.31; Chi Z = 0.84 3.25 11.7	P = 0.1 erimenta 8.24 10.022 ² = 4.25, (P = 0.40 4.2 11.136	0.79); 01) II Total 16 31 47 df = 1 0) 16 31 47	C <u>Mean</u> 9.82 9.9 (P = 0.0 3.12 5.2	8.535 9.051 4); l ² = 7 3.711 5.091	Total V 17 32 49 76% 17 32 49	Sf <u>Veight</u> 21.9% 28.1% 49.9% 21.9%	d. Mean Difference <u>IV. Random, 95% CI</u> -0.10 [-0.79, 0.58] 0.80 [0.28, 1.31] 0.38 [-0.50, 1.26] 0.03 [-0.65, 0.71]	Favours [control] Favours [experimen Std. Mean Difference
Heterogeneity: Chi ² = Test for overall effect D 2.1.1 Mental scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 2.1.2 Motor scale Kang 2015 Min 2013	: Z = 2.50 Expe Mean 8.94 17.6 0.31; Chi Z = 0.84 3.25 11.7 0.16; Chi	P = 0.0 erimenta SD 8.24 10.022 $^{2} = 4.25,$ (P = 0.40 4.2 11.136 $^{2} = 2.68,$	0.79); 01) 11 16 31 47 df = 1 0) 16 31 47 df = 1 0) 16 31 47 df = 1	C <u>Mean</u> 9.82 9.9 (P = 0.0 3.12 5.2	8.535 9.051 4); l ² = 7 3.711 5.091	Total V 17 32 49 76% 17 32 49	St <u>Veight</u> 21.9% 28.1% 49.9% 21.9% 28.2%	 Id. Mean Difference IV. Random, 95% CI -0.10 [-0.79, 0.58] 0.80 [0.28, 1.31] 0.38 [-0.50, 1.26] 0.03 [-0.65, 0.71] 0.75 [0.23, 1.26] 	Favours [control] Favours [experimen Std. Mean Difference
Heterogeneity: Chi ² = Test for overall effect D 2.1.1 Mental scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 2.1.2 Motor scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect:	: Z = 2.50 Expe Mean 8.94 17.6 0.31; Chi Z = 0.84 3.25 11.7 0.16; Chi	P = 0.0 erimenta SD 8.24 10.022 $^{2} = 4.25,$ (P = 0.40 4.2 11.136 $^{2} = 2.68,$	0.79); 01) 11 16 31 47 df = 1 0) 16 31 47 df = 1 31 47 df = 1 31 47	C <u>Mean</u> 9.82 9.9 (P = 0.0 3.12 5.2	8.535 9.051 4); l ² = 7 3.711 5.091	Total V 17 32 49 76% 17 32 49 33%	St Veight 21.9% 28.1% 49.9% 21.9% 28.2% 50.1%	td. Mean Difference <u>IV. Random. 95% CI</u> -0.10 [-0.79, 0.58] 0.80 [0.28, 1.31] 0.38 [-0.50, 1.26] 0.03 [-0.65, 0.71] 0.75 [0.23, 1.26] 0.43 [-0.27, 1.12]	Favours [control] Favours [experimen Std. Mean Difference
Heterogeneity: Chi ² = Test for overall effect D 2.1.1 Mental scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 2.1.2 Motor scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Total (95% Cl)	: Z = 2.50 Expe Mean 8.94 17.6 0.31; Chi Z = 0.84 11.7 0.16; Chi Z = 1.20	P = 0.1 erimenta SD 8.24 10.022 $^2 = 4.25,$ (P = 0.40) 4.2 11.136 $^2 = 2.68,$ (P = 0.23)	0.79); 01) 11 16 31 47 df = 1 0) 16 31 47 df = 1 31 47 94	C Mean 9.82 9.9 (P = 0.0 3.12 5.2 (P = 0.1	$\begin{array}{c} \text{ontrol} \\ \text{SD} \\ \end{array}$ 8.535 9.051 4); $ ^2 = 7$ 3.711 5.091 0); $ ^2 = 6$	Total V 17 32 49 76% 17 32 49 33% 98 1	St <u>Veight</u> 21.9% 28.1% 49.9% 21.9% 28.2%	 Id. Mean Difference IV. Random, 95% CI -0.10 [-0.79, 0.58] 0.80 [0.28, 1.31] 0.38 [-0.50, 1.26] 0.03 [-0.65, 0.71] 0.75 [0.23, 1.26] 	Favours [control] Favours [experimen Std. Mean Difference IV. Random. 95% CI
Heterogeneity: Chi ² = Test for overall effect D 2.1.1 Mental scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 2.1.2 Motor scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Total (95% Cl) Heterogeneity: Tau ² =	: Z = 2.50 Expe Mean 8.94 17.6 0.31; Chi Z = 0.84 3.25 11.7 0.16; Chi Z = 1.20 0.12; Chi	P = 0.1 erimenta SD 8.24 10.022 $^{2} = 4.25,$ (P = 0.40) 4.2 11.136 $^{2} = 2.68,$ (P = 0.23) $^{2} = 6.94,$	0.79); 01) 11 16 31 47 df = 1 0) 16 31 47 df = 1 3) 94 df = 3	C Mean 9.82 9.9 (P = 0.0 3.12 5.2 (P = 0.1	$\begin{array}{c} \text{ontrol} \\ \text{SD} \\ \end{array}$ 8.535 9.051 4); $ ^2 = 7$ 3.711 5.091 0); $ ^2 = 6$	Total V 17 32 49 76% 17 32 49 33% 98 1	St Veight 21.9% 28.1% 49.9% 21.9% 28.2% 50.1%	td. Mean Difference <u>IV. Random. 95% CI</u> -0.10 [-0.79, 0.58] 0.80 [0.28, 1.31] 0.38 [-0.50, 1.26] 0.03 [-0.65, 0.71] 0.75 [0.23, 1.26] 0.43 [-0.27, 1.12]	Favours [control] Favours [experiment Std. Mean Difference IV. Random. 95% CI
Heterogeneity: Chi ² = Test for overall effect D 2.1.1 Mental scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 2.1.2 Motor scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Total (95% Cl)	: Z = 2.50 Expe Mean 8.94 17.6 0.31; Chi Z = 0.84 3.25 11.7 0.16; Chi Z = 1.20 0.12; Chi Z = 1.83	P = 0.0 erimenta SD 8.24 10.022 $^2 = 4.25,$ (P = 0.40) 4.2 11.136 $^2 = 2.68,$ (P = 0.23) $^2 = 6.94,$ (P = 0.07)	0.79); 0.7); 10 11 16 31 47 df = 1 0) 16 31 47 df = 1 0) 94 df = 3 7)	C Mean 9.82 9.9 (P = 0.0 3.12 5.2 (P = 0.1 (P = 0.0	$\begin{array}{c} \text{ontrol} \\ \text{SD} \\ \end{array}$ 8.535 9.051 4); $ ^2 = 7$ 3.711 5.091 0); $ ^2 = 6$ 7); $ ^2 = 5$	Total V 17 32 49 76% 17 32 49 33% 98 1 57%	St Veight 21.9% 28.1% 49.9% 21.9% 28.2% 50.1%	td. Mean Difference <u>IV. Random. 95% CI</u> -0.10 [-0.79, 0.58] 0.80 [0.28, 1.31] 0.38 [-0.50, 1.26] 0.03 [-0.65, 0.71] 0.75 [0.23, 1.26] 0.43 [-0.27, 1.12]	Favours [control] Favours [experimen Std. Mean Difference IV. Random. 95% CI
Heterogeneity: Chi ² = Test for overall effect D 2.1.1 Mental scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 2.1.2 Motor scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Total (95% Cl)	: Z = 2.50 Expe Mean 8.94 17.6 0.31; Chi Z = 0.84 3.25 11.7 0.16; Chi Z = 1.20 0.12; Chi Z = 1.83	P = 0.0 erimenta SD 8.24 10.022 $^2 = 4.25,$ (P = 0.40) 4.2 11.136 $^2 = 2.68,$ (P = 0.23) $^2 = 6.94,$ (P = 0.07)	0.79); 0.7); 10 11 16 31 47 df = 1 0) 16 31 47 df = 1 0) 94 df = 3 7)	C Mean 9.82 9.9 (P = 0.0 3.12 5.2 (P = 0.1 (P = 0.0	$\begin{array}{c} \text{ontrol} \\ \text{SD} \\ \end{array}$ 8.535 9.051 4); $ ^2 = 7$ 3.711 5.091 0); $ ^2 = 6$ 7); $ ^2 = 5$	Total V 17 32 49 76% 17 32 49 33% 98 1 57%	St Veight 21.9% 28.1% 49.9% 21.9% 28.2% 50.1%	td. Mean Difference <u>IV. Random. 95% CI</u> -0.10 [-0.79, 0.58] 0.80 [0.28, 1.31] 0.38 [-0.50, 1.26] 0.03 [-0.65, 0.71] 0.75 [0.23, 1.26] 0.43 [-0.27, 1.12]	Favours [control] Favours [experiment Std. Mean Difference IV. Random. 95% CI
Heterogeneity: Chi ² = Test for overall effect Study or Subgroup 2.1.1 Mental scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 2.1.2 Motor scale Kang 2015 Min 2013 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Test for overall effect: Test for subaroup diffe FIGURE 4	: Z = 2.50 Expe Mean 8.94 17.6 0.31; Chi Z = 0.84 3.25 11.7 0.16; Chi Z = 1.20 0.12; Chi Z = 1.83 erences: C	P = 0.1 erimenta SD 8.24 10.022 $^{2} = 4.25,$ (P = 0.40 4.2 11.136 $^{2} = 2.68,$ (P = 0.23 $^{2} = 6.94,$ (P = 0.07 Chi ² = 0.0	0.79); 01) 1 16 31 47 df = 1 0) 16 31 47 df = 1 0) 94 df = 3 01. df =	C Mean 9.82 9.9 (P = 0.0 3.12 5.2 (P = 0.1 (P = 0.0 1 (P = 0	$\begin{array}{c} \text{ontrol} \\ \text{SD} \\ \end{array}$ 8.535 9.051 4); $ ^2 = 7$ 3.711 5.091 0); $ ^2 = 6$ 7); $ ^2 = 5$ 0.93), $ ^2$	Total V 17 32 49 76% 17 32 49 33% 98 1 57% = 0%	St Veight 21.9% 28.1% 49.9% 21.9% 28.2% 50.1%	 Id. Mean Difference IV. Random, 95% CI -0.10 [-0.79, 0.58] 0.80 [0.28, 1.31] 0.38 [-0.50, 1.26] 0.03 [-0.65, 0.71] 0.75 [0.23, 1.26] 0.43 [-0.27, 1.12] 0.42 [-0.03, 0.87] 	Favours [control] Favours [experiment Std. Mean Difference IV. Random. 95% CI

3.4.3.3 Administration route subgroup of gross motor function measure

As mentioned above, the methods of cell transplantion in the included studies were mainly intravenous and intrathecal injection. Pooled analysis (Figure 6B) showed that SCT significantly increased GMFM scores (SMD = 0.45, 95%CI = 0.20–0.70, p = 0.0005), compared with the control group. Subgroup analysis with random-effects model showed that SCT significantly increased GMFM scores in intrathecal route (SMD = 0.56, 95%CI = 0.25–0.88, p = 0.0004; heterogeneity test p = 0.52; $I^2 = 0\%$). In contrast, no significant

differences were observed in the intravenous subgroup (SMD = 036, 95%CI = -0.09–0.80, p = 0.11; heterogeneity test p = 0.14; $I^2 = 50$ %).

3.4.3.4 Dose subgroup of gross motor function measure

Studies were divided into three grades based on the total number of cells injected: low dose $(4 \times 10^6 - 3 \times 10^7/\text{kg})$, medium-dose $(3-9 \times 10^7/\text{kg})$ and high-dose $(9 \times 10^7 - 5.2 \times 10^8/\text{kg})$. Pooled analysis (Figure 6C) showed that SCT significantly increased GMFM scores (SMD = 0.63, 95%CI = 0.22–1.03, p = 0.002), compared with the control group. Subgroup analysis with

	Ex	perimental			Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.2.1 GMFM 1 month									
Amanat 2021	4.47	15.38	36	-0.02	14.1	36	5.7%	0.30 [-0.16, 0.77]	+
Gu 2020	-1.316	14.95	19	4.053	13.42	20	3.8%	-0.37 [-1.00, 0.26]	
Kang 2015	1.59	1.979	17	1.49	2.185	17	3.5%	0.05 [-0.63, 0.72]	
Min 2013	3.7	2.227	31	4.6	3.394	32	5.2%	-0.31 [-0.81, 0.19]	+
Subtotal (95% CI)			103			105	18.2%	-0.06 [-0.39, 0.27]	•
Heterogeneity: Tau ² = (0.03: Chi	$^{2} = 4.30$, df	= 3 (P	= 0.23):	$l^2 = 30\%$			• • •	
Test for overall effect: 2			- (-	,					
1.2.2 GMFM 3 month									
Amanat 2021	6.85	15.16	36	2.03	14.79	36	5.7%	0.32 [-0.15, 0.78]	+
Gu 2020	32.053	21.92	19	15.7	30.17	20	3.7%	0.60 [-0.04, 1.25]	
Kang 2015	3.65	4.865	17	2.61	2.721	17	3.5%	0.26 [-0.42, 0.93]	
Liu 2017a		33.86561	35		29.07568	17	4.2%	0.48 [-0.11, 1.07]	+ <u>-</u>
Liu 2017b	3.79		35		29.07568	18	4.2%	0.06 [-0.51, 0.62]	
Min 2013	6.5	5.011	31	6.4	3.96	32	4.4 % 5.3%	0.02 [-0.47, 0.52]	
Subtotal (95% CI)	0.5	5.011	173	0.4	5.90	140	26.7%	0.02 [-0.47, 0.52]	•
Heterogeneity: Tau ² = (00.06	2 - 2 10 df		- 0 69).	12 - 00/	140	20.7 /0	0.27 [0.04, 0.43]	•
Test for overall effect: 2			– 5 (P	- 0.00),	1 0 %				
1.2.3 GMFM 6 month									
Amanat 2021	11.27	15.55	36	-0.58	13.86	36	5.4%	0.80 [0.31, 1.28]	
Gu 2020	59	39	19	28.9	39.39	20	3.6%	0.75 [0.10, 1.40]	
Kang 2015	7.08	8.441	13	3.85	3.752	17	3.0%	0.51 [-0.23, 1.24]	+
Liu 2017a	26.79	34.18174	34	4.6	28.84156	17	4.1%	0.67 [0.07, 1.27]	
Liu 2017b	9.08	31.09434	35	4.6	28.84156	18	4.4%	0.15 [-0.42, 0.71]	
Min 2013	9.1	6.681	31	7.8	5.091	32	5.3%	0.22 [-0.28, 0.71]	
Subtotal (95% CI)			168			140	25.9%	0.51 [0.27, 0.74]	•
Heterogeneity: Tau² = 0 Test for overall effect: 2				= 0.41);	l² = 2%				
		(,						
1.2.4 GMFM 12 month				1.00	10.10	0.0	F = 0/	0.0410.17.4.45	
Amanat 2021	10.65	15.55	36	1.23	13.49	36	5.5%	0.64 [0.17, 1.11]	
Gu 2020	64.526	41.85	19	36.8	8.802	20	3.6%	0.91 [0.25, 1.57]	
Liu 2017a		34.35075	33		28.75533	17	4.1%	0.74 [0.14, 1.35]	
Liu 2017b		31.24451	34		28.75533	18	4.4%	0.29 [-0.28, 0.87]	
Luan 2012	5.69	2.91	45	3.92	2.33	49	6.4%	0.67 [0.25, 1.09]	
Sun 2017	7.5	6.8	32	6.9	5.5	31	5.3%	0.10 [-0.40, 0.59]	
Subtotal (95% CI)			199			171	29.2%	0.54 [0.31, 0.77]	•
Heterogeneity: Tau ² = (Test for overall effect: 2				= 0.31);	l² = 17%				
Total (95% CI)			643			556	100.0%	0.35 [0.21, 0.50]	•
Heterogeneity: Tau ² = ().04; Chi	² = 32.07. d		P = 0.0	6); ² = 35%			-	
Test for overall effect: 2 Test for subaroup differ	2 = 4.73 ((P < 0.0000	1)		,,				-2 -1 0 1 2 Favours [control] Favours [experiment
FIGURE 5									
Time subgroup of G	MEM								
	111111								

random-effects model showed that SCT significantly increased GMFM scores in low dose (SMD = 0.60, 95%CI = 0.35–0.85, p < 0.00001; heterogeneity test p = 0.69; $I^2 = 0\%$). However, the analysis results were not statistically significant at medium (SMD = 0.22, 95%CI = -0.10–0.54, p = 0.17) and high doses (SMD = 1.15, 95%CI = -0.48–2.78, p = 0.17).

3.4.3.5 CP type subgroup of gross motor function measure

In the study of Amanat et al. (2021) and Liu et al. (2017) mentioned above, only patients with spastic CP were included, while other studies' patients with CP were not classified.

Therefore, we performed subgroup analysis on GMFM score for CP type (Supplementary Material S5A). The results suggested that SCT was effective in both spastic (SMD: 0.56; 95%CI [0.25, 0.88]; p = 0.0004; heterogeneity test p = 0.52; $I^2 = 0\%$) and unclassified CP (SMD: 0.45; 95%CI [0.16, 0.74]; p = 0.002; heterogeneity test p = 0.22; $I^2 = 31\%$) compared with the control group. But the difference between subgroups showed no statistically significance (p = 0.61, $I^2 = 0\%$).

3.4.3.6 Age subgroup of gross motor function measure

The age range of patients included in the study was 0.5-15, and the mean age of the treatment groups ranged from 1 to

4.1 MaC wanal 2021 0.165 15.55 36 1.23 13.49 36 21.6% 0.64 [0.17, 1.11] 30 2020 64.526 41.85 19 36.8 8.202 20 12.6% 0.64 [0.17, 1.11] 30 2020 64.526 41.85 19 36.8 8.202 20 12.6% 0.51 [0.25, 1.57] 30 2010 0.01 ChiP = 0.42, df = 2 (P = 0.61); P = 0% 68 57.51 20.275 [0.40, 0.56] 9 61 70 2013 5.1 6.681 31 7.8 5.53 32.202.8% 0.22 [-0.26, 0.71] 61 (95% C1) 7.6 8.441 13 3.65 5.73 2.203 0.01 (-0.40, 0.56] 61 (95% C1) 7.6 6.84, df = 6 (P = 0.20); P = 10%; eat for overall effoct: 2 = 3.69 (P = 0.20); P = 10%; eat for overall effoct: 2 = 3.69 (P = 0.20); P = 10%; eat for overall effoct: 2 = 3.69 (P = 0.20); P = 10%; eat for overall effoct: 2 = 3.69 (P = 0.20); P = 0.26; P = 10%; eat for overall effoct: 2 = 3.69 (P = 0.20); P = 0.26; P =		Mean	perimental SD	Total	Mean	Control SD	Total	Weight	Std. Mean Difference IV. Random. 95% Cl	Std. Mean Difference IV. Random. 95% Cl
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	I.6.1 MSC									
Gu 2020 44.228 41.85 19 3.68 8.02 20 12.6% 0.91 $[0.25, 1.57]$ Lik 2017a 31.82 43.5975 33 7.25 28.7653 17 14.7% 0.74 $[0.14, 1.35]$ Trail for overall field 22 44.3 $(2 - 0.05)$ $1^{-0} - 0.51$ $1^{-0} - 0.55$ Trail for overall field 22 44.3 $(2 - 0.05)$ $1^{-0} - 0.55$ $1^{-0} - 0.55$ Trail for overall field 22 44.3 $(2 - 0.05)$ $1^{-0} - 0.55$ Trail for overall field 22 44.3 $(2 - 0.05)$ $1^{-0} - 0.55$ Trail for overall field 22 44.3 $(2 - 0.05)$ $1^{-0} - 0.25$ Subtotal (95% C) Trail for overall field 22 $4-3.7$ $(P - 0.05)$ $1^{-0} - 0.05)$ Trail for overall field 22 $4-3.7$ $(P - 0.05)$ Trail for overall field 22 $4-3.7$ $(P - 0.05)$ $1^{-0} - 0.05)$ Trail for overall field 22 $4-3.7$ $(P - 0.05)$ Trail for overall field 22 $4-3.7$ $(P - 0.05)$ Trail for overall field 22 $4-3.7$ $(P - 0.05)$ $1^{-0} - 0.05$ Trail for overall field 22 $4-3.7$ $(P - 0.05)$ Trail for overall field 22 $4-3.5$ $(P - 0.05)$ $1^{-0} - 0.25$ $1^{-0} - 0.5$ Trail for overall field 22 $4-3.5$ $(P - 0.05)$ $1^{-0} - 0.25$ $1^{-0} - 0.5$ Trail for overall field 22 $4-3.5$ $(P - 0.05)$ $1^{-0} - 0.55$ $1^{-0} - 0.55$ Trail for overall field 22 $4-3.5$ $(P - 0.05)$ $1^{-0} - 0.55$ Trail for overall field 22 $4-3.5$ $(P - 0.05)$ $1^{-0} - 0.55$ $1^{-0} - 0.55$ Trail for overall field 22 $4-3.5$ $(P - 0.05)$ $1^{-0} - 0.55$ Trail for overall field 22 $4-3.5$ $(P - 0.05)$ $1^{-0} - 0.55$ Trail for overall field 22 $4-3.5$ $(P - 0.05)$ $1^{-0} - 0.55$ Trail for overall field 22 $4-3.5$ $(P - 0.05)$ $1^{-0} - 0.55$ Trail for overall field 22 $4-3.5$ $(P - 0.05)$ $1^{-0} - 0.55$ Trail for overall field 22 $4-3.5$ $(P - 0.05)$ $1^{-0} - 0.5$	Amanat 2021	10.65	15.55	36	1.23	13.49	36	21.6%	0.64 [0.17. 1.11]	
Lung 2018 1266 3.429 27 4.81 2.205 27 2.75 [1.9, 3.50] 12 4.14 (1.4, 1.55] 14 2.75 2.87.553 17 14.7%, 0.74 (1.4, 1.55] 14 2.55 31 7.25 2.87.553 17 14.7%, 0.74 (1.4, 1.55] 14 2.55 31 7.25 2.87.553 17 14.7%, 0.74 (1.4, 1.55] 14 2.55 31 7.2 4.8.9%, 0.73 [0.41, 1.06] 14 2.55 (1.4, 1.4, 1.55] 14 2.55 31 7.2 (1.5, 1.5, 1.5, 1.5, 1.5, 1.5, 1.5, 1.5,										
$\begin{aligned} \begin{array}{c} \mbox{Lu} \ Dir \ Dir$										_ _
Subtoral (95% C) 10^{-10} $10^$	•							14 7%		•
Hearcognelly: Tar $t = 0.00$, Ch ² = 0.42, df = 2 ($P = 0.81$); P = 0% Tarl for overall effect: $Z = 4.43$ ($P < 0.0001$) 16.2 UCB Kang 2015 7.08 8.441 13 3.85 3.752 17 10.5% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 8.509 32 20.2% 0.22 [-0.28, 0.71] Sanctol (9% C) Hearcognelly: Tarl $= 0.02$, Ch ² = 0.76 df = 6 ($P = 0.85$); P = 0% Tarl for overall effect: $Z = 3.89$ ($P = 0.0002$) Tarl for overall effect: $Z = 3.89$ ($P = 0.0002$); P = 10%; Tarl for overall effect: $Z = 3.89$ ($P = 0.0002$); P = 0.39; P = 78 7% Subtoral (9% C) Hearcognelly: Tarl $= 0.02$, Ch ² = 0.783, df = 1 ($P = 0.39$); P = 717 7% Subtoral (9% C) Hearcognelly: Tarl $= 0.02$, Ch ² = 0.783, df = 1 ($P = 0.39$); P = 718 7% Subtoral (9% C) Hearcognelly: Tarl $= 0.02$, Ch ² = 0.783, df = 1 ($P = 0.39$); P = 718 7% Subtoral (9% C) Hearcognelly: Tarl $= 0.02$, Ch ² = 0.783, df = 1 ($P = 0.39$); P = 718 7% Subtoral (9% C) Hearcognelly: Tarl $= 0.02$, Ch ² = 0.733, df = 1 ($P = 0.39$); P = 718 7% Subtoral (9% C) Hearcognelly: Tarl $= 0.02$, Ch ² = 1.52, CH = 0.33, P = 728 7% Subtoral (9% C) Hearcognelly: Tarl $= 0.02$, Ch ² = 1.53, df = 1 ($P = 0.48$); P = 798 Subtoral (9% C) Hearcognelly: Tarl $= 0.02$, Ch ² = 1.33, df = 2 ($P = 0.52$); P = 0% Tarl for overall effect: $Z = 3.89$ ($P = 0.000$) Tarl for audition Ga 2020 Get 256 df 18 7, 6 8 8, 8022 20 12.1% OSI [0.25, 0.88] Hearcognelly: Tarl $= 0.02$, Ch ² = 4.74, df = 2 ($P = 0.25$); P = 2% Subtoral (9% C) Hearcognelly: Tarl $= 0.02$, Ch ² = 4.74, df = 5 ($P = 0.14$); P = 50% Tarl for overall effect: $Z = 1.58$ ($P = 0.14$) To tarl (9% C) Hearcognelly: Tarl $= 0.02$, Ch ² = 4.74, df = 5 ($P = 0.26$); P = 0% Tarl for overall effect: $Z = 3.89$ ($P = 0.26$); P = 0% Tarl for audition Ga 2020 Get 23 3 37.445 13 7.52 28.7533 11 8 2% 0.22 (-28.0571) Hearcognelly: Tarl $= 0.02$, Ch ² = 4.74, df = 5 ($P = 0.26$); P = 0% Tarl for overall effect: $Z = 3.89$ ($P = 0.26$); P = 0% Tarl for overall effect: $Z = 3.89$ ($P = 0.26$); P = 0% Tarl for overal		0.1.02				2011 0000				
Test for overall effect: $Z = 4.43$ ($P < 0.0001$) 16.2 UCB Kang 2015 7.08 8.441 13 3.85 3.752 17 10.5% 0.51 [0.23, 1.24] Min 2013 9.1 6.881 31 7.8 5.091 32 20.2% 0.22 [0.28, 0.71] Statotal (9% C) Tat for sourcell effect: $Z = 3.02$ ($P = 0.66$); $P = 0.36$ Test for overall effect: $Z = 3.62$ ($P = 0.66$); $P = 0.32$; $P = 0.36$ Test for overall effect: $Z = 3.62$ ($P = 0.32$); $P = 19\%$ Test for overall effect: $Z = 3.62$ ($P = 0.022$); $P = 0.37$ Test for overall effect: $Z = 3.62$ ($P = 0.022$); $P = 0.37$ Test for overall effect: $Z = 3.62$ ($P = 0.022$); $P = 0.37$ Test for overall effect: $Z = 3.62$ ($P = 0.022$); $P = 0.37$ Test for overall effect: $Z = 3.62$ ($P = 0.022$); $P = 0.37$ Test for overall effect: $Z = 3.62$ ($P = 0.022$); $P = 0.37$ Test for overall effect: $Z = 3.62$ ($P = 0.022$); $P = 0.37$ Test for overall effect: $Z = 3.62$ ($P = 0.022$); $P = 0.37$ Test for overall effect: $Z = 3.62$ ($P = 0.022$); $P = 0.37$ Test for overall effect: $Z = 3.62$ ($P = 0.022$); $P = 0.37$ Test for overall effect: $Z = 3.62$ ($P = 0.022$); $P = 0.37$ Test for overall effect: $Z = 3.53$ ($P = 0.024$); $P = 0.37$ Test for overall effect: $Z = 3.53$ ($P = 0.024$); $P = 0.37$ Test for overall effect: $Z = 3.54$ ($P = 0.026$); $P = 0.37$; $P = 0.37$ Test for overall effect: $Z = 3.54$ ($P = 0.026$); $P = 0.37$; $P = 0.37$ Test for overall effect: $Z = 3.54$ ($P = 0.026$); $P = 0.37$; $P = 0.37$ Test for overall effect: $Z = 3.54$ ($P = 0.026$); $P = 0.37$; $P = 0.37$ Test for overall effect: $Z = 3.54$ ($P = 0.026$); $P = 0.37$; $P = 0.37$ Test for overall effect: $Z = 3.54$ ($P = 0.026$); $P = 0.37$; $P = 0.37$ Test for overall effect: $Z = 3.54$ ($P = 0.026$); $P = 0.37$; $P = 0.37$ Test for overall effect: $Z = 3.54$ ($P = 0.026$); $P = 0.37$; $P = 0.37$ Test for overall effect: $Z = 3.54$ ($P = 0.026$); $P = 0.37$; $P = 0.37$ Test for overall effect: $Z = 3.54$ ($P = 0.026$); $P = 0.37$; $P = 0.37$ Test for overall effect: $Z = 3.54$ ($P = 0.026$); $P = 0.37$; $P = 0.37$ Te		0.00; Chi ²	² = 0.42, df	= 2 (P =	= 0.81);	$ ^2 = 0\%$				
Gang 2015 7.08 8.441 13 3.85 3.752 17 10.5% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 20.2% 0.22 [-0.28, 0.71] Survey of the 0.82, df = 2 (P = 0.69); $F = 0\%$ Test for overall effect: $Z = 1.37$ ($P = 0.17$) Total (69%, C) 164 155 16.55 36 12.3 13.49 36 20.4% 0.48 [0.22, 0.73] Test for overall effect: $Z = 3.69$ ($P = 0.29$); $P = 19\%$ Test for overall effect: $Z = 3.69$ ($P = 0.29$); $P = 19\%$ Test for overall effect: $Z = 3.69$ ($P = 0.29$); $P = 19\%$ Survey of Subroau Mean SD Total Mean SD Total Mean Mean SD Total Mean Mean SD Total Mean Mean Mean Mean Mean Mean Mean Mean					,,					
$\begin{aligned} \begin{tabular}{ c $	1.6.2 UCB									+
Sup 2017 7. 7.5 6.8 32 6.9 5.5 31 20.3% 0.10 [0.40, 0.59] Heterogeneity: Tarl = 0.0; Ch ² = 0.82, df = 2 (P = 0.68); P = 0% Test for overall effect: $Z = 1.37$ (P = 0.17) Total (9% C) 164 0.22, ch ² = 0.22; P = 0.80; P = 0% Test for overall effect: $Z = 3.6$ (P = 0.20); P = 19% Test for overall effect: $Z = 3.6$ (P = 0.002) Test for subprove differences: Ch ² = 4.33, df = 1 (P = 0.03); P = 7.7% Subprove differences: Ch ² = 4.33, df = 1 (P = 0.03); P = 7.7% Subprove differences: Ch ² = 4.33, df = 1 (P = 0.03); P = 7.7% Subprove differences: Ch ² = 4.33, df = 1 (P = 0.03); P = 7.7% Subprove differences: Ch ² = 4.33, df = 1 (P = 0.03); P = 7.7% Subprove differences: Ch ² = 4.33, df = 1 (P = 0.03); P = 7.7% Subprove differences: Ch ² = 4.33, df = 1 (P = 0.03); P = 7.7% Subprove differences: Ch ² = 4.33, df = 1 (P = 0.03); P = 7.7% Subprove differences: Ch ² = 4.33, df = 2 (P = 0.52); P = 0% Test for overall effect: Z = 3.567 (P = 0.26); P = 0.57; P = 0% Test for overall effect: Z = 3.57 (P = 0.004) Heterogeneity: Tarl ² = 0.00; Ch ² = 1.30, df = 2 (P = 0.52); P = 0% Test for overall effect: Z = 3.46 (P = 0.004) Heterogeneity: Tarl ² = 0.00; Ch ² = 1.30, df = 2 (P = 0.43); P = 50% Test for overall effect: Z = 3.46 (P = 0.004) Heterogeneity: Tarl ² = 0.00; Ch ² = 4.37, df = 5 (P = 0.26); P = 23%; Test for overall effect: Z = 3.46 (P = 0.005) Test for subprove differences: Ch ² = 0.56, df = 1 (P = 0.46); P = 0% Test for overall effect: Z = 3.47 (P = 0.46); P = 0% Test for overall effect: Z = 3.47 (P = 0.46); P = 0% Test for overall effect: Z = 4.72 (P < 0.0001) Heterogeneity: Tarl ² = 0.00; Ch ² = 4.37, df = 5 (P = 0.26); P = 23%; Test for 0.86 (D = 0.69); P = 0% Test for overall effect: Z = 4.72 (P < 0.0001) Heterogeneity: Tarl ² = 0.00; Ch ² = 4.74, df = 3 (P = 0.66); P = 0% Test for overall effect: Z = 4.72 (P < 0.0001) Heterogeneity: Tarl ² = 0.00; Ch ² = 0.66); P = 0% Test for overall effect: Z = 1.37 (P = 0.17) Heterogeneity: Tarl ² = 0.00; Ch ² = 0.66);	Kang 2015	7.08	8.441	13	3.85	3.752	17	10.5%	0.51 [-0.23, 1.24]	
Subtotal (95% C) 7. 76 8. 80 91.1% 0.22 [c_{10} 0.64] Heterogeneity: Tau ² = 0.05; Ch ² = 0.20; P = 0.66]; P = 0% Test for overall effect: Z = 3.37 (P = 0.17) Total (95% C) 164 153 100.0% 0.48 [0.22, 0.7] Heterogeneity: Tau ² = 0.02; Ch ² = 0.20; P = 2.0% Test for overall effect: Z = 3.89 (P = 0.0002) Test for overall effect: Z = 3.89 (P = 0.0002) Test for subcroup differences: Ch ² = 4.83, df = 1 (P = 0.03), P = 79.7K Std. Mean Difference Kudy or Subgroup Mean SD Total Mean SD Total Weight N. Random. 95% Cl N. Random. 95% Cl 1.01. Intrathese Total Amand: 0.201 (10.65 15.55 36 1.23 13.49 36 2.0.4% 0.64 [0.17, 1.11] Lu 2017b 16.23 31.24451 34 7.25 28.75633 18 15.2% 0.24 [0.28, 0.87] Subtotal (95% C) 103 Ch ² = 1.30, df = 2 (P = 0.52); P = 0% Test for overall effect: Z = 3.38 (P = 0.0004) 1.10.2 intravenous infusion Gu 2020 64.526 41.85 19 36.8 8.802 20 12.1% 0.91 [0.25, 1.57] Heterogeneity: Tau ² = 0.00; Ch ² = 4.30, df = 2 (P = 0.25); P = 0% Test for overall effect: Z = -3.38 (P = 0.0004) 1.10.2 intravenous infusion Gu 2020 64.526 41.85 19 36.8 8.802 20 12.1% 0.91 [0.25, 1.57] Heterogeneity: Tau ² = 0.00; Ch ² = 4.30, df = 2 (P = 0.11) Total (95% Cl) 185 194 0.00; Ch ² = 4.30, df = 2 (P = 0.26); P = 23% Test for overall effect: Z = -1.00; Ch ² = 4.74, df = 1 (P = 0.46); P = 0.56; Test for overall effect: Z = -3.84 (P = 0.005) Test for subcroup differences: Ch ² = 0.55; df = 1 (P = 0.46); P = 23% Charlence Ch ² = 0.00; Ch ² = 4.43, df = 1 (P = 0.46); P = 0.56 Std. Mean Difference Std. Mean D	Min 2013	9.1	6.681	31	7.8	5.091	32	20.2%	0.22 [-0.28, 0.71]	
Herogeneity: Tat ² = 0.00; Ch ² = 0.82, df = 2 (P = 0.66); P = 0% Test for overall effect: $Z = 1.37$ (P = 0.17) Total (5%; C) 164 153 100.0% 0.48 [0.22, 0.73] Letter overall effect: $Z = 3.6$ (P = 0.29); P = 1% Test for overall effect: $Z = 3.6$ (P = 0.29); P = 1% Test for overall effect: $Z = 3.6$ (P = 0.002) Test for subprove difference: Ch ² = 4.93, df = 1 (P = 0.03), P = 7.7% Std. Mean Difference: Ch ² = 4.93, df = 1 (P = 0.03), P = 7.7% Std. Mean Difference: Std. Mean Difference Std. Mean Difference: Std. Mean Difference: Std. Mean Difference Std. Mean Difference: Std. Mean Difference Std. Mean Difference: Std. Mean Difference Std. Mean Difference: V: Random, 95% CI Meangeneity: Tat ² = 0.05; Ch ² = 4.05; df = 1 (P = 0.46); P = 23% Std. Mean Difference: V: Random, 95% CI Meangeneity: Tat ² = 0.05; Ch ² = 4.7, df = 5 (P = 0.26); P = 23% Std. Mean Difference: V: Random, 95% CI Meangeneity: Tat ² = 0.05; Ch ² = 4.7, df = 5 (P = 0.26); P = 23% Std. Mean Difference Std. Mean Difference Std. Mean Difference N: Random, 95% CI Meangeneity: Tat ² = 0.05; Ch ² = 0.66); P = 0% Std. Mean Difference N: Random, 95% CI Meangeneity: Tat ² = 0.0; Ch ² = 0.66); P = 0% Std. Mean Difference N: Random, 95% CI Meangeneity: Tat ² = 0.0; Ch ² = 0.66);	Sun 2017	7.5	6.8	32	6.9	5.5	31		0.10 [-0.40, 0.59]	•
Test for overall effect: $Z = 1.37$ ($P = 0.17$) Total (9% C) 1 164 153 100.0% 0.48 (0.22, 0.73) Test for vorall effect: $Z = 3.6$ ($P = 0.0002$) Test for vorall effect: $Z = 3.6$ ($P = 0.0002$) Test for vorall effect: $Z = 3.6$ ($P = 0.0002$) Test for vorall effect: $Z = 3.6$ ($P = 0.0002$) Test for vorall effect: $Z = 3.6$ ($P = 0.0002$) Test for vorall effect: $Z = 3.6$ ($P = 0.0002$) Test for vorall effect: $Z = 3.6$ ($P = 0.0002$) Test for vorall effect: $Z = 3.6$ ($P = 0.0002$) Test for vorall effect: $Z = 3.6$ ($P = 0.0002$) Test for vorall effect: $Z = 3.6$ ($P = 0.0002$) Test for vorall effect: $Z = 3.6$ ($P = 0.0004$) Test for vorall effect: $Z = 3.6$ ($P = 0.0004$) Test for vorall effect: $Z = 3.6$ ($P = 0.0004$) Total (95% C) Test for vorall effect: $Z = 3.6$ ($P = 0.0004$) Total (95% C) Test for vorall effect: $Z = 3.6$ ($P = 0.0004$) Total (95% C) Test for vorall effect: $Z = 3.6$ ($P = 0.0004$) Total (95% C) Test for vorall effect: $Z = 3.6$ ($P = 0.0004$) Test for vorall effect: $Z = 3.6$ ($P = 0.0004$) Test for vorall effect: $Z = 3.6$ ($P = 0.0004$) Test for vorall effect: $Z = 3.6$ ($P = 0.0004$) Test for vorall effect: $Z = 3.6$ ($P = 0.0004$) Test for vorall effect: $Z = 3.6$ ($P = 0.0005$) Test for vorall effect: $Z = 3.6$ ($P = 0.0005$) Test for vorall effect: $Z = 3.6$ ($P = 0.0005$) Test for vorall effect: $Z = 3.6$ ($P = 0.0005$) Test for vorall effect: $Z = 3.6$ ($P = 0.0005$) Test for vorall effect: $Z = 3.6$ ($P = 0.0005$) Test for vorall effect: $Z = 3.6$ ($P = 0.0005$) Test for vorall effect: $Z = 3.6$ ($P = 0.0005$) Test for vorall effect: $Z = 3.6$ ($P = 0.0005$) Test for vorall effect: $Z = 3.6$ ($P = 0.0005$) Test for vorall effect: $Z = 3.6$ ($P = 0.0005$) Test for vorall effect: $Z = 3.6$ ($P = 0.0005$) Test for vorall effect: $Z = 3.6$ ($P = 0.06$); $P = 0\%$ Test for vorall effect: $Z = 3.6$ ($P = 0.06$); $P = 0\%$ Test for vorall effect: $Z = 4.72$ ($P = 0.06$); $P = 0\%$ Test for vorall effect: $Z = 4.72$ ($P = 0.06$); $P = 0.6$;							80	51.1%	0.22 [-0.10, 0.54]	
Heterogeneity: $Tat^2 = 0.02$; $P = 0.002$) Test for suborou differences: $Ch^2 = 4.93$, $df = 1$ ($P = 0.29$); $P = 79.7\%$ Study or Suborou differences: $Ch^2 = 4.93$, $df = 1$ ($P = 0.03$); $P = 79.7\%$ Study or Suborou differences: $Ch^2 = 4.93$, $df = 1$ ($P = 0.03$); $P = 79.7\%$ Study or Suborou differences: $Ch^2 = 4.93$, $df = 1$ ($P = 0.03$); $P = 79.7\%$ Study or Suborou differences: $Ch^2 = 4.93$, $df = 1$ ($P = 0.03$); $P = 79.7\%$ Study or Suborou differences: $Ch^2 = 4.93$, $df = 1$ ($P = 0.03$); $P = 79.7\%$ Study or Suborou differences: $Ch^2 = 4.93$, $df = 2$ ($P = 0.032$); $P = 0.032$, $P = 0.033$, $P = 0.032$, $P = 0.032$, $P = 0.033$, $P = 0.032$, $P = 0.033$, P				= 2 (P =	= 0.66);	l ² = 0%				
Helerogeneity: $Tau^2 = 0.02$; $P = 0.002$) Test for suborou differences Study or Suborou difference Study or Sub	Total (95% CI)			164			153	100.0%	0.48 [0.22, 0.73]	
Test for overall effect: Z = 3.69 (P = 0.002) Test for subgroup difference: Study or Subgroup Mean SD Total Mean SD Total Weight (V. Random, 55% CI V. Random, 55	2002 0 000 0 0 0 0	0.02: Chi ²	² = 6.18. df		= 0.29):	l² = 19%	5.5			
Tast for subcroup difference: $Ch^{\mu} = 4.93, df = 1 (P = 0.03), P = 79.7%.$ Std. Mean Difference Std. Mean Difference Std. Mean Difference Std. Mean Difference Market Provided Provi					<u>_</u> o),					⊢avours [control] Favours [experimental]
Experimental Control Std. Mean Difference Std. Mean Std. Mean <thstd. mean<="" th=""> <thstd. mean<="" th=""> <t< td=""><td></td><td></td><td></td><td></td><td>P = 0.0</td><td>3), l² = 79.7</td><td>%</td><td></td><td></td><td></td></t<></thstd.></thstd.>					P = 0.0	3), l ² = 79.7	%			
Study or Subgroup Mean SD Total Mean SD Total Mean SD Total Weight IV. Random. 95% Cl IV. Subprise Interval and IV. Subprise IV. Subp							-		Std Moon Difference	Std Moon Difference
1.10.1 intrathecal route Amanat 2021 10.65 15.55 36 1.23 13.49 36 204% 0.64 [0.17, 1.11] Li 2017a 16.23 31.2445 34 7.25 28.75533 17 14.0% 0.74 [0.14, 1.35] Li 2017b 16.23 31.2445 34 7.25 28.75533 17 14.0% 0.74 [0.14, 1.35] Li 2017b 16.23 31.2445 34 7.25 28.75533 17 14.0% 0.74 [0.28, 0.71] Subtotal (95% CI) 0.000 Chi ² = 1.30, df = 2 ($P = 0.52$); $P = 0\%$ Test for overall effect: $Z = 3.53$ ($P = 0.0004$) 1.10.2 Intravenous infusion Gu 2020 64.526 41.85 19 36.8 8.802 20 12.1% 0.91 [0.25, 1.57] Min 2013 9.1 6.681 31 7.8 5.091 32 191.0% 0.22 [0.28, 0.71] Subtotal (95% CI) 82 83 50.4% 0.36 [-0.09, 0.80] Heterogeneity: Tau ² = 0.00; Chi ² = 4.00, df = 2 ($P = 0.46$); $P = 0\%$ Test for overall effect: $Z = 3.49$ ($P = 0.0005$) Test for overall effect: $Z = 1.58$ ($P = 0.26$); $P = 2.3\%$ Test for overall effect: $Z = 3.49$ ($P = 0.0005$) Test for overall effect: $Z = 3.49$ ($P = 0.0005$) Test for overall effect: $Z = 3.49$ ($P = 0.0005$) Test for subtroup differences: Chi = 0.55, 36 1.23 13.49 36 10.6% 0.44 [0.17, 1.11] Li 2017b 16.23 31.24451 34 7.25 28.75533 17 9.7% 0.74 [0.14, 1.35] Li 2017b 16.23 31.24451 34 7.25 28.75533 17 9.7% 0.74 [0.14, 1.35] Li 2017b 16.23 31.24451 34 7.25 28.75533 17 9.7% 0.74 [0.14, 1.35] Li 2017b 16.23 31.24451 34 7.25 28.75533 17 9.7% 0.74 [0.14, 1.35] Li 2017b 16.23 31.24451 34 7.25 28.75533 17 9.7% 0.74 [0.14, 1.35] Li 2017b 16.23 31.24451 34 7.25 28.75533 17 9.7% 0.74 [0.14, 1.35] Li 2017b 16.23 31.24451 34 7.25 28.75533 17 9.7% 0.74 [0.14, 1.35] Li 2017b 16.23 31.24451 34 7.25 28.75533 17 9.7% 0.74 [0.14, 1.35] Li 2017b 16.23 31.24451 34 7.25 28.75533 17 9.7% 0.74 [0.14, 1.35] Li 2017b 16.23 31.24451 34 7.25 28.75533 17 9.7% 0.74 [0.14, 1.35] Li 2017b 16.23 31.24451 34 7.25 28.75533 11 9.9\% 0.29 [0.28, 0.71] Subtotal (95% CI) 76 8.441 13 3.85 3.752 17 8.8\% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 10.5\% 0.22 [-0.28, 0.71] Subtotal (95% CI) 76 8.441 13 3.85 3.752 17 8.8\% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 10.05\% 0.010				Total	Mean		Total			
Anamat 2021 10.65 15.55 36 1.23 13.49 36 20.4% 0.64 [0.17, 1.11] Liu 2017a 31.82 34.35075 33 7.25 28.7553 17 14.0% 0.74 [0.14, 1.35] Liu 2017b 16.23 31.24451 34 7.25 28.7553 17 14.0% 0.74 [0.24, 0.87] Subtotal (95% CI) 103 77 48.6% 0.29 (0.28, 0.88] Heterogeneity: Tau" = 0.00; Ch ² = 1.30, df = 2 ($P = 0.52$); $P = 0\%$ Test for overall effect: $Z = 3.53 (P = 0.0004)$ 1.102 Intravenous infusion Gu 2020 64.526 41.85 19 36.8 8.802 20 12.1% 0.91 [0.25, 1.57] Min 2013 9.1 6.681 31 7.8 5.091 32 19.1% 0.022 [0.28, 0.79] Subtotal (95% CI) 82 0.06 (df = 2 ($P = 0.14$); $P = 50\%$ Test for overall effect: $Z = 3.68 (P = 0.005$) Test for overall effect: $Z = 3.68 (P = 0.01)$ Total (95% CI) 185 154 100.0% 0.45 [0.20, 0.70] Heterogeneity: Tau" = 0.02; Ch ² = 6.47, df = 5 ($P = 0.26$); $P = 23\%$ Test for overall effect: $Z = 3.68 (P = 0.013)$ Total (95% CI) 185 154 100.0% 0.45 [0.20, 0.70] Heterogeneity: Tau" = 0.02; Ch ² = 6.47, df = 5 ($P = 0.26$); $P = 23\%$ Test for overall effect: $Z = 3.48 (P = 0.005)$ Test for overall effect: $Z = 3.48 (P = 0.005)$ Test for overall effect: $Z = 3.48 (P = 0.005)$; $P = 0\%$ Test for overall effect: $Z = 3.48 (P = 0.69)$; $P = 0\%$ Test for varial effect: $Z = 3.47 (P = 0.46)$, $P = 0\%$ Test for varial effect: $Z = 3.47 (P = 0.69)$; $P = 0\%$ Test for overall effect: $Z = 4.72 (P < 0.00001)$ 19.2 medium dose Kang 2015 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.22 [-0.28, 0.87] Heterogeneity: Tau" = 0.00; Ch ² = 0.47, df = 3 (P = 0.69); $P = 0\%$ Test for overall effect: $Z = 4.72 (P < 0.00001)$ 19.2 medium dose Kang 2015 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.22 [-0.28, 0.71] Subtotal (95% CI) 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.22 [-0.28, 0.71] Subtotal (95% CI) 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.22 [-0.28, 0.71] Min 2015 9.1			30	iotai	mean	30	Total	mergint	14, Randolli, 55 /6 Cl	17, Nandoni, 33 /0 01
Li 2017a 31.82 34.36076 33 7.25 28.7553 17 14.0% 0.74 [0.14, 1.35] Li 2017b 16.23 31.24451 34 7.25 28.7553 18 152.% 0.29 [0.28, 0.87] Subtotal (95% CI) 103 71 49.6% 0.56 [0.25, 0.86] Heterogeneity: Tau ² = 0.0004) 1.10.2 Intravenous infusion Gu 2020 64.526 41.85 19 36.8 8.802 20 12.1% 0.91 [0.25, 1.57] Min 2013 9.1 6.681 31 7.8 5.091 32 191.% 0.22 [0.28, 0.71] Sun 2017 7.5 6.8 32 6.9 5.5 31 19.2% 0.10 [0.40, 0.59] Heterogeneity: Tau ² = 0.00; ChP = 4.00, df = 2 (P = 0.46). P = 0% Test for overall effect: Z = 3.40 (P = 0.0005) Test for overall effect: Z = 3.40 (P = 0.0005) Test for overall effect: Z = 3.49 (P = 0.0005) Test for overall effect: Z = 3.49 (P = 0.0005) Test for subarous differences: Ch P = 0.46). P = 0%. Experimental Control Std. Mean Differences Study or Subarous Mean SD Total Mean SD Total Weight IV. Random 39% CI 1.3.1 fow does Amanat 2021 10.65 15.55 36 1.23 13.49 36 10.6% 0.44 [0.17, 1.11] Liu 2017b 16.23 31.24451 34 7.25 28.75533 11 9.9% 0.29 [0.28, 0.87] Heterogeneity: Tau ² = 0.00; Ch ² = 1.46, df = 3 (P = 0.69); P = 0% Test for subarous differences: Ch P = 1.46, df = 3 (P = 0.69); P = 0% Test for overall effect: Z = 4.72 (P < 0.00001) Haterogeneity: Tau ² = 0.00; Ch ² = 1.46, df = 3 (P = 0.69); P = 0% Test for overall effect: Z = 4.72 (P < 0.00001) 1.9.2 medium dose Kang 2015 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.22 [-0.28, 0.87] Liu 2017b 16.23 312.4451 34 7.25 28.75533 11 9.9% 0.22 [-0.28, 0.87] Liu 2017b 16.23 312.4451 34 7.25 28.75533 11 9.9% 0.22 [-0.28, 0.87] Liu 2017b 16.82 312.4451 34 7.25 28.75533 11 9.9% 0.22 [-0.28, 0.71] Subtotal (95% CI) 76 8.8 421 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.22 [-0.28, 0.71] Subtotal (95% CI) 76 8.8 32 6.9 5.5 31 10.5% 0.22 [-0.28, 0.71] Subtotal (95% CI) 76 8.8 32 6.9 5.5 31 10.5% 0.22 [-0.28, 0.51] Heterogeneity: Tau ² = 0.00; Ch ² = 0.68]; P = 0.68]; P = 0.68 Subtotal (95% CI) 76 8.44 15 19 36.8 8.802			15 55	36	1.23	13 40	36	20.4%	0.64 [0.17 1.11]	
Liu 2017b 16.23 31:24451 34 7.25 28.75533 18 15.2% 0.29 [$0.28, 0.87$] Heterogeneity: Tau ² = 0.00; Chi ² = 1.30, df = 2 (P = 0.52); l ² = 0% Test for overall effect Z = 3.53 (P = 0.0004) 1.10.2 intravenous infusion Gu 2020 64.526 41.85 19 36.8 8.802 20 12.1% 0.91 [0.25, 1.57] Min 2013 9.1 6.681 31 7.8 5.091 32 19.1% 0.22 [$-0.80, 0.71$] Subtotal (95% CI) 82 83 50.4% 0.36 [$-0.09, 0.80$] Heterogeneity: Tau ² = 0.08; Chi ² = 4.00, df = 2 (P = 0.14); l ² = 50% Test for overall effect Z = 1.58 (P = 0.11); Total (95% CI) 185 154 100.0% 0.45 [0.20, 0.70] Heterogeneity: Tau ² = 0.02; Chi ² = 6.47, df = 5 (P = 0.26); l ² = 23% Test for overall effect Z = 1.58 (P = 0.14); l ² = 50% Test for overall effect Z = 1.58 (P = 0.14); l ² = 50% Test for overall effect Z = 1.58 (P = 0.26); l ² = 23% Subtotal (95% CI) 185 154 100.0% 0.45 [0.20, 0.70] Heterogeneity: Tau ² = 0.02; Chi ² = 6.47, df = 5 (P = 0.26); l ² = 23% Test for overall effect Z = 3.49 (P = 0.005) Test for overall effect Z = 3.18 (P = 0.05); df = 1 (P = 0.46), l ² = 0.0% Subtotal (95% CI) 185 36 123 13.49 36 10.6% 0.64 [0.17, 1.11] Liu 2017b 16.23 31.24451 34 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Lua 2012 5.69 2.51 45 3.92 2.33 49 11.0% 0.67 [0.25, 1.09] Subtotal (95% CI) 148 123 8.2 (2.7553 18 9.9% 0.29 [-0.28, 0.87] Lua 2012 5.69 2.51 445 3.92 2.33 49 11.0% 0.61 [0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.22 [-0.28, 0.71] Subtotal (95% CI) 175 6.8 32 2 6.9 5.5 31 10.5% 0.22 [-0.28, 0.71] Subtotal (95% CI) 7.5 6.8 32 6.9 5.5 31 10.5% 0.22 [-0.28, 0.71] Subtotal (95% CI) 7.5 6.8 32 6.9 5.5 31 10.5% 0.22 [-0.28, 0.71] Subtotal (95% CI) 7.5 6.8 32 2 6.9 5.5 31 10.5% 0.22 [-0.28, 0.71] Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.22 [-0.28, 0.71] Subtotal (95% CI) 7.5 6.8 32 6.9 5.5 31 0.5% 0.22 [-0.28, 0.71] Subtotal (95% CI) 7.5 6.8 32 6.9 5.5 31 0.5% 0.22 [-0.28, 0.71] Subtotal (95% CI) 7.5 6.8 32 6.9 5.5 31 0.5% 0.22 [-0.28, 0.71] Subtotal (95% CI) 7.5 6.8 32 6.9 5.5 31 0.5% 0.22 [-0.28, 0.71] Min										
Subtotal (95% CI) 103 71 49.6% 0.56 [0.25, 0.88] Heterogeneity: Tau ² = 0.00; Chi ² = 1.30, df = 2 (P = 0.52); I ² = 0% Test for overall effect: Z = 3.53 (P = 0.004) 1.10.2 intravenous infusion Gu 2020 64.526 41.85 19 36.8 8.802 20 12.1% 0.91 [0.25, 1.57] Min 2013 9.1 6.681 31 7.8 5.091 32 19.1% 0.22 [0.28, 0.71] Sun 2017 7.5 6.8 32 6.9 5.5 31 19.2% 0.10 [-0.40, 0.59] Subtotal (95% CI) 82 83 50.4% 0.36 [-0.09, 0.80] Heterogeneity: Tau ² = 0.02; Chi ² = 6.47, df = 6 (P = 0.26); I ² = 5% Test for overall effect: Z = 3.49 (P = 0.0005) Test for subprroup differences: Chi ² = 0.55, df = 1 (P = 0.46), I ² = 0% Test for overall effect: Z = 3.49 (P = 0.0005) Test for subprroup differences: Chi ² = 0.55, df = 1 (P = 0.46), I ² = 0% Test for subprroup differences: Chi ² = 0.55, df = 1 (P = 0.46), I ² = 0% Test for subprroup differences: Chi ² = 0.55, df = 1 (P = 0.46), I ² = 0% Test for subprroup differences: Chi ² = 0.55, df = 1 (P = 0.46), I ² = 0% Test for subprroup differences: Chi ² = 0.55, df = 1 (P = 0.46), I ² = 0% Test for subprroup differences: Chi ² = 0.55, df = 1 (P = 0.46), I ² = 0% Test for overall effect: Z = 3.12, 445 13 3.49 36 10.6% 0.64 [0.17, 1.11] Liu 2017h 18.23 31.24451 33 7.25 28.75533 11 9.9% 0.29 [-0.28, 0.87] Luan 2012 5.69 2.91 45 3.92 2.33 49 11.0% 0.67 [0.25, 1.09] Subtotal (95% CI) 148 120 41.2% 0.60 [0.35, 0.85] Heterogeneity: Tau ² = 0.00; Chi ² = 1.46, df = 3 (P = 0.69); I ² = 0% Test for overall effect: Z = 4.72 (P < 0.00001) 19.2 medium dose Kang 2015 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.10 [0.40, 0.59] Subtotal (95% CI) 7.5 6.8 32 6.9 5.5 31 10.5% 0.10 [-0.40, 0.59] Subtotal (95% CI) 7.6 8 3.429 2.7 4.81 2.026 2.7 8.6% 2.75 [1.99, 3.50] Heterogeneity: Tau ² = 0.00; Chi ² = 0.83, df = 2 (P = 0.66); I ² = 0% Test for overall effect: Z = 1.37 (P = 0.47) Heterogeneity: Tau ² = 0.07; Chi ² = 4.48, df = 2 (P < 0.0001); I ² = 9%										+
Heterogeneity: Tau ² = 0.00; Ch ² = 1.30, df = 2 (P = 0.52); P ² = 0% Test for overall effect: Z = 3.53 (P = 0.0004) 1.102 intravenous infusion Gu 2020 64 526 41.85 19 36.8 8.802 20 12.1% 0.91 [0.25, 1.57] Min 2013 9.1 6.681 31 7.8 5.091 32 19.1% 0.22 [-0.28, 0.71] Subtotal (95% Cl) 7.5 6.8 32 6.9 5.5 31 19.2% 0.10 [-0.40, 0.59] Heterogeneity: Tau ² = 0.08; Ch ² = 4.00, df = 2 (P = 0.14); P ² = 50% Test for overall effect: Z = 1.58 (P = 0.11) Total (95% Cl) 185 154 100.0% 0.45 [0.20, 0.70] Heterogeneity: Tau ² = 0.02; Chi ² = 6.47, df = 5 (P = 0.26); P ² = 23% Test for overall effect: Z = 3.49 (P = 0.0005) Test for subtrou offferences: Ch ² = 0.53 11 9.2% 0.45 [0.20, 0.70] Heterogeneity: Tau ² = 0.02; Chi ² = 6.47, df = 5 (P = 0.46); P ² = 0% Test for subtrou offferences: Ch ² = 0.53 17.5 28.7553 17 9.7% 0.74 [0.14, 1.35] Liu 2017b 16.23 31.24451 34 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Liu 2017b 16.23 31.24451 34 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Liu 2017b 16.23 31.24451 34 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Liu 2017b 16.23 31.24451 34 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Liu 2017b 16.23 31.24451 34 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Liu 2017b 16.23 31.24451 34 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Liu 2017b 16.23 31.24451 34 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Liu 2017b 16.23 31.24451 34 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Liu 2017b 16.23 31.24451 34 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Liu 2017b 16.23 31.24451 34 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Liu 2017b 16.861 31 7.8 5.091 32 10.5% 0.010 [-0.40, 0.59] Subtotal (95% Cl) 75 6.8 32 6.9 5.5 31 10.5% 0.010 [-0.40, 0.59] Subtotal (95% Cl) 75 6.8 32 6.9 5.5 31 10.5% 0.010 [-0.40, 0.59] Subtotal (95% Cl) 75 76 8.8 02 9.9.3% 0.91 [0.25, 1.57] Heterogeneity: Tau ² = 0.00; Ch ² = 0.82, df = 2 (P = 0.66); P = 0% Test for overall effect: Z = -1.37 (P = 0.17) 13.3 high dose Gu 2020 64.526 41.85 19 36.8 8.802 20 9.3% 0.91 [0.25, 1.57] Heterogeneity: Tau ² = 1.97; Ch ² =		10.20	51.24401		1.20	20.10000				•
Gu 2020 64.526 41.85 19 36.8 8.802 20 12.1% 0.91 [0.25, 1.57] Min 2013 9.1 6.681 31 7.8 5.091 32 19.1% 0.22 [-0.20, 0.71] Subtotal (95% CI) 82 83 50.4% 0.36 [-0.99, 0.80] Heterogeneity: Tau ² = 0.02; Chi ² = 6.47, df = 5 (P = 0.26); P = 23% Test for overall effect: Z = 1.58 (P = 0.01) Test for overall effect: Z = 0.25; Chi ² = 6.47, df = 5 (P = 0.26); P = 23% Test for overall effect: Z = 0.25; Chi ² = 6.47, df = 5 (P = 0.26); P = 0.46); P = 0% Experimental Control Std. Mean Difference Std. Mean Difference Std					= 0.52);	l² = 0%				
Min 2013 9.1 6.681 31 7.8 5.091 32 19.1% 0.22 $[0.28, 0.71]$ Sun 2017 7.5 6.8 32 6.9 5.5 31 19.2% 0.10 $[-0.40, 0.59]$ Subtotal (95% CI) 82 83 50.4% 0.36 $[-0.90, 0.80]$ Heterogeneity: Tau ² = 0.08; Ch ² = 4.00, df = 2 (P = 0.14); P = 50% Test for overall effect: Z = 1.58 (P = 0.11) Total (95% CI) 185 154 100.0% 0.45 $[0.20, 0.70]$ Heterogeneity: Tau ² = 0.02; Ch ² = 6.47, df = 5 (P = 0.26); P = 23% Test for overall effect: Z = 3.49 (P = 0.0005) Test for suborou differences: Ch ² = 0.55, df = 1 (P = 0.46); P = 0% Study or Subgroup Mean SD Total Mean SD Total Weight IV. Random, 95% CI IV. Random, 95% CI 19.1 low dose Annant 2021 10.65 15.55 36 1.23 13.49 36 10.6% 0.64 $[0.17, 1.11]$ Liu 2017b 16.23 31.24451 34 7.25 28.75633 17 9.7% 0.74 $[0.14, 1.35]$ Liu 2017b 16.23 31.24451 34 7.25 2.83.75633 17 9.7% 0.74 $[0.14, 1.35]$ Liu 2017b 16.23 31.24451 34 7.25 2.83.75633 18 9.9% 0.29 $[-0.28, 0.87]$ Liu 2017b 16.23 31.24451 34 7.25 2.33 49 11.0% 0.67 $[0.25, 1.09]$ Subtotal (95% CI) 48 8.441 13 3.85 3.752 17 8.8% 0.51 $[-0.23, 1.24]$ Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.00 $[0.35, 0.85]$ Heterogeneity: Tau ² = 0.00; Ch ² = 1.46, df = 2 (P = 0.66); P = 0% Test for overall effect: Z = 4.72 (P < 0.00001) 19.2 medium dose Kang 2015 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 $[-0.23, 1.24]$ Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.01 $[-0.40, 0.59]$ Subtotal (95% CI) 75 6.8 32 6.9 5.5 31 10.5% 0.01 $[-0.40, 0.59]$ Subtotal (95% CI) 76 8.8.421 $[2 = 0.66]; P = 0\%$ Test for overall effect: Z = 1.37 (P = 0.17) 19.3 high dose Gu 2020 64.526 41.85 19 36.8 8.802 20 9.3% 0.91 $[0.25, 1.57]$ Huang 2015 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 $[1.90, 3.50]$ Rah 2017 0.3725 0.188 47 0.4 0.188 47 11.0% -0.15 $[-0.56, 0.26]$ Subtotal (95% CI) 72 $[-0.82, df = 2 (P < 0.66); P = 0\%$ Test for overall effect: Z = 1.37 (Ch ² = 44.66, df = 2 (P < 0.00001); P = 96\%	1.10.2 intravenous ir	fusion								
Min 2013 9.1 6.681 31 7.8 5.091 32 19.1% 0.22 $[0.28, 0.71]$ Sun 2017 7.5 6.8 32 6.9 5.5 31 19.2% 0.10 $[-0.40, 0.59]$ Subtotal (95% CI) 82 83 50.4% 0.36 $[-0.90, 0.80]$ Heterogeneity: Tau ² = 0.08; Ch ² = 4.00, df = 2 (P = 0.14); P = 50% Test for overall effect: Z = 1.58 (P = 0.11) Total (95% CI) 185 154 100.0% 0.45 $[0.20, 0.70]$ Heterogeneity: Tau ² = 0.02; Ch ² = 6.47, df = 5 (P = 0.26); P = 23% Test for overall effect: Z = 3.49 (P = 0.0005) Test for suborou differences: Ch ² = 0.55, df = 1 (P = 0.46); P = 0% Study or Subgroup Mean SD Total Mean SD Total Weight IV. Random, 95% CI IV. Random, 95% CI 19.1 low dose Annant 2021 10.65 15.55 36 1.23 13.49 36 10.6% 0.64 $[0.17, 1.11]$ Liu 2017b 16.23 31.24451 34 7.25 28.75633 17 9.7% 0.74 $[0.14, 1.35]$ Liu 2017b 16.23 31.24451 34 7.25 2.83.75633 17 9.7% 0.74 $[0.14, 1.35]$ Liu 2017b 16.23 31.24451 34 7.25 2.83.75633 18 9.9% 0.29 $[-0.28, 0.87]$ Liu 2017b 16.23 31.24451 34 7.25 2.33 49 11.0% 0.67 $[0.25, 1.09]$ Subtotal (95% CI) 48 8.441 13 3.85 3.752 17 8.8% 0.51 $[-0.23, 1.24]$ Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.00 $[0.35, 0.85]$ Heterogeneity: Tau ² = 0.00; Ch ² = 1.46, df = 2 (P = 0.66); P = 0% Test for overall effect: Z = 4.72 (P < 0.00001) 19.2 medium dose Kang 2015 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 $[-0.23, 1.24]$ Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.01 $[-0.40, 0.59]$ Subtotal (95% CI) 75 6.8 32 6.9 5.5 31 10.5% 0.01 $[-0.40, 0.59]$ Subtotal (95% CI) 76 8.8.421 $[2 = 0.66]; P = 0\%$ Test for overall effect: Z = 1.37 (P = 0.17) 19.3 high dose Gu 2020 64.526 41.85 19 36.8 8.802 20 9.3% 0.91 $[0.25, 1.57]$ Huang 2015 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 $[1.90, 3.50]$ Rah 2017 0.3725 0.188 47 0.4 0.188 47 11.0% -0.15 $[-0.56, 0.26]$ Subtotal (95% CI) 72 $[-0.82, df = 2 (P < 0.66); P = 0\%$ Test for overall effect: Z = 1.37 (Ch ² = 44.66, df = 2 (P < 0.00001); P = 96\%	Gu 2020	64.526	41.85	19	36.8	8.802	20	12.1%	0.91 [0.25, 1.57]	— -
Sun 2017 7.5 6.8 32 6.9 5.5 31 19.2% 0.10 [0.40, 0.59] Subtotal (95% CI) 82 83 50.4% 0.36 [-0.09, 0.80] Heterogeneity: Tau ² = 0.08; Ch ² = 4.00, of = 2 (P = 0.14); I ² = 50% Test for overall effect. Z = 1.58 (P = 0.11) Total (95% CI) 185 154 100.0% 0.45 [0.20, 0.70] Heterogeneity: Tau ² = 0.02; Ch ² = 6.47, df = 5 (P = 0.26); I ² = 23% Test for overall effect. Z = 3.49 (P = 0.0005) Test for subarous differences: Ch ² = 0.55. df = 1 (P = 0.46). I ² = 0% Experimental Control Std. Mean Differences Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI IV, Random,	Min 2013	9.1	6.681	31	7.8	5.091	32	19.1%		
Subtal (95% CI) 82 83 50.4% 0.36 [-0.09, 0.80] Heterogeneity: Tau ² = 0.08; Ch ² = 4.00, df = 2 (P = 0.14); l ² = 50% Test for overall effect: Z = 1.58 (P = 0.11) Total (95% CI) 185 154 100.0% 0.45 [0.20, 0.70] Heterogeneity: Tau ² = 0.02; Ch ² = 6.47, df = 5 (P = 0.26); l ² = 23% Test for overall effect: Z = 3.49 (P = 0.0005) Test for overall effect: Z = 3.49 (P = 0.0005) Experimental Control Std. Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight IV. Random, 95% CI 1.9.1 low dose Annant 2021 10.65 15.55 36 1.23 13.49 36 10.6% 0.64 [0.17, 1.11] Liu 2017h 16.23 31.2444 13 47 7.25 28.75533 17 9.7% 0.74 [0.14, 1.35] Liua 2017h 16.23 31.2444 13 47 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Heterogeneity: Tau ² = 0.00; Ch ² = 1.46, df = 3 (P = 0.69); l ² = 0% Test for overall effect: Z = 4.72 (P < 0.00001) 1.9.2 medium dose Kang 2015 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] Min 2013 9.1 6.661 31 7.8 5.091 32 10.5% 0.22 [-0.28, 0.71] Subtotal (95% CI) 76 8.824 6f = 3 (P = 0.66); l ² = 0% Test for overall effect: Z = 1.37 (P = 0.17) 1.9.3 high dose Gu 2020 Ch ² = 0.82, df = 2 (P = 0.66); l ² = 0% Test for overall effect: Z = 1.37 (P = 0.17) 1.9.3 high dose Gu 2020 64.526 41.85 19 36.8 8.802 20 9.3% 0.91 [0.25, 1.57] Huang 2018 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 [1.99, 3.50] Subtotal (95% CI) 83 Heterogeneity: Tau ² = 0.07; Ch ² = 4.6.66; l ² = 0 (A - 0.166); l ² = 0% Test for overall effect: Z = 1.37 (P = 0.17) 1.9.3 high dose Gu 2020 64.526 41.85 19 36.8 8.802 20 9.3% 0.91 [0.25, 1.57] Huang 2018 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 [1.99, 3.50] Subtotal (95% CI) 83 Heterogeneity: Tau ² = 1.97; Ch ² = 4.6.66, df = 2 (P < 0.00001); l ² = 96% Test for overall effect: Z = 1.37 (P = 0.17) 1.9.3 high dose Gu 2020 64.526 41.85 19 36.8 8.802 20 9.3% 0.91 [0.25, 1.57] Huang 2018 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 [1.99, 3.50] Subtotal (95% CI) 83 Heterogeneity: Tau ² = 1.97; Ch ² = 4.6.66, df = 2 (P < 0.00001); l ² = 96%	Sun 2017	7.5	6.8		6.9	5.5	31	19.2%		
Test for overall effect: $Z = 1.58$ (P = 0.11) Total (95% Cl) 185 154 100.0% 0.45 [0.20, 0.70] Heterogeneity: Tau ² = 0.02; Chi ² = 6.47, df = 5 (P = 0.26); l ² = 23% Test for overall effect: $Z = 3.49$ (P = 0.0005) Test for overall effect: $Z = 3.49$ (P = 0.0005) Experimental Control Std. Mean Difference: Study or Subgroup Mean SD Total Mean SD Total Weight IV. Random, 95% Cl IV.	Subtotal (95% CI)			82			83	50.4%	0.36 [-0.09, 0.80]	←
Test for overall effect: $Z = 3.49$ (P = 0.0005) Test for subaroup differences: Chi ² = 0.55. df = 1 (P = 0.46). ² = 0% Experimental Control Std. Mean Difference Std. Mean Difference Std. Mean Difference IV. Random. 95% Cl 1.9.1 low dose Amanat 2021 1 0.65 15.55 36 1.23 13.49 36 10.6% 0.64 [0.17, 1.11] Liu 2017a 31.82 34.35075 33 7.25 28.75533 17 9.7% 0.74 [0.14, 1.35] Liu 2017b 16.23 31.24451 34 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Luan 2012 5.69 2.91 45 3.92 2.33 49 11.0% 0.67 [0.25, 1.09] Subtotal (95% Cl) 148 120 41.2% 0.60 [0.35, 0.85] Heterogeneity: Tau ² = 0.00; Chi ² = 1.46, df = 3 (P = 0.69); l ² = 0% Test for overall effect: Z = 4.72 (P < 0.00001) 1.9.2 medium dose Kang 2015 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.22 [-0.28, 0.71] Subtotal (95% Cl) 76 80 29.8% 0.22 [-0.10, 0.54] Heterogeneity: Tau ² = 0.00; Chi ² = 0.82, df = 2 (P = 0.66); l ² = 0% Test for overall effect: Z = 1.37 (P = 0.17) 1.9.3 high dose Gu 2020 64.526 41.85 19 36.8 8.802 20 9.3% 0.91 [0.25, 1.57] Huang 2018 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 [1.99, 3.50] Rah 2017 0.3725 0.188 47 0.4 0.188 47 11.0% -0.15 [-0.55, 0.26] Subtotal (95% Cl) 93 94 29.0% 1.15 [-0.48, 2.78] Heterogeneity: Tau ² = 1.97; Chi ² = 44.69, df = 2 (P < 0.00001); l ² = 9%				= 2 (P =	- 0.14),	1 50%				
Study or Subgroup Mean SD Total Mean SD Total Weight IV. Random. 95% Cl IV. Random. 95% Cl 1.9.1 low dose Amanat 2021 10.65 15.55 3 7.25 28.75533 17 9.7% 0.64 [0.17, 1.11] IV. Random. 95% Cl Liu 2017a 31.82 34.35075 33 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Lua 2012 5.69 2.91 45 3.92 2.33 49 11.0% 0.67 [0.25, 1.09] Subtotal (95% Cl) 148 120 41.2% 0.60 [0.35, 0.85] \bullet Heterogeneity: Tau ² = 0.00; Chi ² = 1.46, df = 3 (P = 0.69); l ² = 0% 120 41.2% 0.60 [0.35, 0.85] \bullet 19.2 medium dose Kang 2015 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] \bullet \bullet Min 2013 9.1 6.681 31 7.8 5.091 32 0.5% 0.22 [-0.28, 0.71] \bullet \bullet \bullet	Total (95% CI)	Z = 1.58 (P = 0.11)	185			154	100.0%	0.45 [0.20, 0.70]	• · · ·
Study or Subgroup Mean SD Total Mean SD Total Weight IV. Random. 95% CI IV. Random. 95% CI 1.9.1 low dose Amanat 2021 10.65 15.55 36 1.23 13.49 36 10.6% 0.64 [0.17, 1.11] Liu 2017a 31.82 34.35075 33 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Luan 2012 5.69 2.91 45 3.92 2.33 49 11.0% 0.67 [0.25, 1.09] Subtotal (95% CI) 148 120 41.2% 0.60 [0.35, 0.85] + Heterogeneity: Tau ² = 0.00; Chi ² = 1.46, df = 3 (P = 0.69); l ² = 0% Test for overall effect: Z = 4.72 (P < 0.00001) +	Total (95% CI) Heterogeneity: Tau² = Test for overall effect:	Z = 1.58 (0.02; Chi ² Z = 3.49 (P = 0.11) ² = 6.47, df P = 0.0005	185 = 5 (P =	= 0.26);	l² = 23%	154	100.0%	0.45 [0.20, 0.70]	-2 -1 0 1 2 Favours [control] Favours [experimental]
1.9.1 low dose Amanat 2021 10.65 15.55 36 1.23 13.49 36 10.6% 0.64 [0.17, 1.11] Liu 2017a 31.82 34.35075 33 7.25 28.75533 18 9.9% 0.74 [0.14, 1.35] Liu 2017b 16.23 31.24451 34 7.25 28.75533 18 9.9% 0.29 [0.28, 0.87] Luan 2012 5.69 2.91 45 3.92 2.33 49 11.0% 0.67 [0.25, 1.09] Subtotal (95% CI) 148 120 41.2% 0.60 [0.35, 0.85] Heterogeneity: Tau ² = 0.00; Chi ² = 1.46, df = 3 (P = 0.69); l ² = 0% Test for overall effect: Z = 4.72 (P < 0.00001) 1.9.2 medium dose Kang 2015 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.10 [-0.40, 0.59] Subtotal (95% CI) 75 6.8 32 6.9 5.5 31 10.5% 0.22 [-0.28, 0.71] Subtotal (95% CI) 76	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe	Z = 1.58 (0.02; Chi ² Z = 3.49 (erences: C	P = 0.11) $P^{2} = 6.47, df$ P = 0.0005 $hi^{2} = 0.55.$	185 = 5 (P =	= 0.26);	I² = 23% 6). I² = 0%	154			Favours [control] Favours [experimental]
Amanat 2021 10.65 15.55 36 1.23 13.49 36 10.6% 0.64 [0.17, 1.11] Liu 2017a 31.82 34.35075 33 7.25 28.75533 17 9.7% 0.74 [0.14, 1.35] Liu 2017b 16.23 31.24451 34 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Liu 2017b 16.23 31.24451 34 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Liu 2012 5.69 2.91 45 3.92 2.33 49 11.0% 0.67 [0.25, 1.09] Subtotal (95% CI) 148 120 41.2% 0.60 [0.35, 0.85] Heterogeneity: Tau ² = 0.00; Chi ² = 1.46, df = 3 (P = 0.69); l ² = 0% Test for overall effect: Z = 4.72 (P < 0.00001) 1.9.2 medium dose Kang 2015 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] Win 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.22 [-0.28, 0.71] Sun 2017 7.5 6.8 32 6.9 5.5 31 10.5% 0.10 [-0.40, 0.59] Subtotal (95% CI) 76 80 29.8% 0.22 [-0.10, 0.54] Heterogeneity: Tau ² = 0.00; Chi ² = 0.82, df = 2 (P = 0.66); l ² = 0% Test for overall effect: Z = 1.37 (P = 0.17) 1.9.3 high dose Gu 2020 64.526 41.85 19 36.8 8.802 20 9.3% 0.91 [0.25, 1.67] Huang 2018 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 [1.99, 3.50] Rah 2017 0.3725 0.188 47 0.4 0.188 47 11.0% -0.15 [-0.55, 0.26] Subtotal (95% CI) 93 94 29.0% 1.15 [-0.48, 2.78] Heterogeneity: Tau ² = 1.97; Chi ² = 44.69, df = 2 (P < 0.00001); l ² = 96%	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for suboroup diffe	Z = 1.58 (0.02; Chi ² Z = 3.49 (erences: C Ext	P = 0.11) $P^{2} = 6.47, df$ P = 0.0005 $hi^{2} = 0.55.$ perimental	185 = 5 (P =) df = 1 ()	= 0.26); P = 0.4	² = 23% 6). ² = 0% Control			Std. Mean Difference	Favours [control] Favours [experimental] Std. Mean Difference
Liu 2017a 31.82 34.35075 33 7.25 28.75533 17 9.7% 0.74 [0.14, 1.35] Liu 2017b 16.23 31.24451 34 7.25 28.75533 18 9.9% 0.29 [-0.28, 0.87] Luan 2012 5.69 2.91 45 3.92 2.33 49 11.0% 0.67 [0.25, 1.09] Subtotal (95% Cl) 148 120 41.2% 0.60 [0.35, 0.85] Heterogeneity: Tau ² = 0.00; Chi ² = 1.46, df = 3 (P = 0.69); l ² = 0% Test for overall effect: $Z = 4.72$ (P < 0.00001) 1.9.2 medium dose Kang 2015 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.22 [-0.28, 0.71] Subtotal (95% Cl) 76 80 29.8% 0.22 [-0.28, 0.71] Subtotal (95% Cl) 76 80 29.8% 0.22 [-0.28, 0.71] Heterogeneity: Tau ² = 0.00; Chi ² = 0.82, df = 2 (P = 0.66); l ² = 0% Test for overall effect: $Z = 1.37$ (P = 0.17) 1.9.3 high dose Gu 2020 64.526 41.85 19 36.8 8.802 20 9.3% 0.91 [0.25, 1.57] Huang 2018 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 [1.99, 3.50] Rah 2017 0.3725 0.188 47 0.4 0.188 47 11.0% -0.15 [-0.55, 0.26] Subtotal (95% Cl) 93 94 29.0% 1.15 [-0.48, 2.78] Heterogeneity: Tau ² = 1.97; Chi ² = 44.69, df = 2 (P < 0.00001); l ² = 96%	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for suboroup diffe Study or Subgroup	Z = 1.58 (0.02; Chi ² Z = 3.49 (erences: C Ext	P = 0.11) $P^{2} = 6.47, df$ P = 0.0005 $hi^{2} = 0.55.$ perimental	185 = 5 (P =) df = 1 ()	= 0.26); P = 0.4	² = 23% 6). ² = 0% Control			Std. Mean Difference	Favours [control] Favours [experimental] Std. Mean Difference
Liu 2017b 16.23 31.24451 34 7.25 28.75533 18 9.9% $0.29[-0.28, 0.87]$ Luan 2012 5.69 2.91 45 3.92 2.33 49 11.0% 0.67 [0.25, 1.09] Subtotal (95% CI) 148 120 41.2% 0.60 [0.35, 0.85] Heterogeneity: Tau ² = 0.00; Chi ² = 1.46, df = 3 (P = 0.69); l ² = 0% Test for overall effect: Z = 4.72 (P < 0.00001) 1.9.2 medium dose Kang 2015 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.22 [-0.28, 0.71] Sun 2017 7.5 6.8 32 6.9 5.5 31 10.5% 0.10 [-0.40, 0.59] Subtotal (95% CI) 76 80 29.8% 0.22 [-0.10, 0.54] Heterogeneity: Tau ² = 0.00; Chi ² = 0.82, df = 2 (P = 0.66); l ² = 0% Test for overall effect: Z = 1.37 (P = 0.17) 1.9.3 high dose Gu 2020 64.526 41.85 19 36.8 8.802 20 9.3% 0.91 [0.25, 1.57] Huang 2018 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 [1.99, 3.50] Rah 2017 0.3725 0.188 47 0.4 0.188 47 11.0% -0.15 [-0.55, 0.26] Subtotal (95% CI) 93 94 29.0% 1.15 [-0.48, 2.78] Heterogeneity: Tau ² = 1.97; Chi ² = 44.69, df = 2 (P < 0.00001); l ² = 96%	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe Study or Subgroup 1.9.1 low dose	Z = 1.58 (0.02; Chi ² Z = 3.49 (erences: C Exp Mean	P = 0.11) ² = 6.47, df : P = 0.0005 hi ² = 0.55. c perimental SD	185 = 5 (P =) df = 1 (I Total	= 0.26); ⊃ = 0.4 <u>Mean</u>	² = 23% 6). ² = 0% Control SD	Total	Weight	Std. Mean Difference IV. Random. 95% Cl	Favours [control] Favours [experimental] Std. Mean Difference
Luan 2012 5.69 2.91 45 3.92 2.33 49 11.0% 0.67 [0.25, 1.09] Subtotal (95% CI) 148 120 41.2% 0.60 [0.35, 0.85] Heterogeneity: Tau ² = 0.00; Chi ² = 1.46, df = 3 (P = 0.69); l ² = 0% Test for overall effect: $Z = 4.72$ (P < 0.00001) 1.9.2 medium dose Kang 2015 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.22 [-0.28, 0.71] Sun 2017 7.5 6.8 32 6.9 5.5 31 10.5% 0.10 [-0.40, 0.59] Subtotal (95% CI) 76 88 0 29.8% 0.22 [-0.10, 0.54] Heterogeneity: Tau ² = 0.00; Chi ² = 0.82, df = 2 (P = 0.66); l ² = 0% Test for overall effect: $Z = 1.37$ (P = 0.17) 1.9.3 high dose Gu 2020 64.526 41.85 19 36.8 8.802 20 9.3% 0.91 [0.25, 1.57] Huang 2018 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 [1.99, 3.50] Rah 2017 0.3725 0.188 47 0.4 0.188 47 11.0% -0.15 [-0.55, 0.26] Subtotal (95% CI) 93 94 29.0% 1.15 [-0.48, 2.78] Heterogeneity: Tau ² = 1.97; Chi ² = 44.69, df = 2 (P < 0.00001); l ² = 96%	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subarouo diffe Study or Subgroup 1.9.1 low dose Amanat 2021	Z = 1.58 (0.02; Chi ² Z = 3.49 (erences: C Exp Mean 10.65	P = 0.11) ² = 6.47, df P = 0.0005 hi ² = 0.55, d perimental SD 15.55	185 = 5 (P =) df = 1 () <u>Total</u> 36	= 0.26); P = 0.4 <u>Mean</u> 1.23	² = 23% 6). ² = 0% Control SD 13.49	Total 36	<u>Weight</u> 10.6%	Std. Mean Difference IV. Random. 95% Cl 0.64 [0.17, 1.11]	Favours [control] Favours [experimental] Std. Mean Difference
Subtotal (95% CI) 148 120 41.2% 0.60 [0.35, 0.85] Heterogeneity: Tau ² = 0.00; Chi ² = 1.46, df = 3 (P = 0.69); I ² = 0% Test for overall effect: Z = 4.72 (P < 0.00001)	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for suboroup diffe Study or Subgroup 1.9.1 low dose Amanat 2021 Liu 2017a	Z = 1.58 (0.02; Chi ² Z = 3.49 (erences: C Exp Mean 10.65 31.82	P = 0.11) $P = 0.47, df = 0.0005$ $P = 0.0005$ $P = 0.55.$ SD 15.55 34.35075	185 = 5 (P =) df = 1 (1 <u>Total</u> 36 33	= 0.26); P = 0.4 <u>Mean</u> 1.23 7.25	² = 23% 6). ² = 0% Control 5D 13.49 28.75533	<u>Total</u> 36 17	Weight 10.6% 9.7%	Std. Mean Difference IV. Random. 95% Cl 0.64 [0.17, 1.11] 0.74 [0.14, 1.35]	Favours [control] Favours [experimental] Std. Mean Difference
Heterogeneity: Tau ² = 0.00; Chi ² = 1.46, df = 3 (P = 0.69); I ² = 0% Test for overall effect: $Z = 4.72$ (P < 0.00001) 1.9.2 medium dose Kang 2015 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] Vin 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.22 [-0.28, 0.71] Sun 2017 7.5 6.8 32 6.9 5.5 31 10.5% 0.10 [-0.40, 0.59] Subtotal (95% Cl) 76 80 29.8% 0.22 [-0.10, 0.54] Heterogeneity: Tau ² = 0.00; Chi ² = 0.82, df = 2 (P = 0.66); I ² = 0% Test for overall effect: $Z = 1.37$ (P = 0.17) 1.9.3 high dose Su 2020 64.526 41.85 19 36.8 8.802 20 9.3% 0.91 [0.25, 1.57] Huang 2018 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 [1.99, 3.50] Rah 2017 0.3725 0.188 47 0.4 0.188 47 11.0% -0.15 [-0.55, 0.26] Subtotal (95% Cl) 93 94 29.0% 1.15 [-0.48, 2.78]	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe Study or Subgroup 1.9.1 low dose Amanat 2021 Liu 2017a Liu 2017b	Z = 1.58 (0.02; Chi ^a Z = 3.49 (erences: C Exp Mean 10.65 31.82 16.23	$P = 0.11)$ $P = 0.47, df = 0.0005$ $P = 0.0005$ $hi^{2} = 0.55.$ operimental SD 15.55 34.35075 31.24451	185 = 5 (P =) df = 1 (1 <u>Total</u> 36 33 34	= 0.26); = = 0.4 <u>Mean</u> 1.23 7.25 7.25	² = 23% 6). ² = 0% Control 5D 13.49 28.75533 28.75533	Total 36 17 18	Weight 10.6% 9.7% 9.9%	Std. Mean Difference IV. Random. 95% Cl 0.64 [0.17, 1.11] 0.74 [0.14, 1.35] 0.29 [-0.28, 0.87]	Favours [control] Favours [experimental] Std. Mean Difference
Kang 2015 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.22 [-0.28, 0.71] Sun 2017 7.5 6.8 32 6.9 5.5 31 10.5% 0.10 [-0.40, 0.59] Subtotal (95% CI) 76 80 29.8% 0.22 [-0.10, 0.54] Heterogeneity: Tau ² = 0.00; Chi ² = 0.82, df = 2 (P = 0.66); l ² = 0% 80 29.8% 0.22 [-0.10, 0.54] Heterogeneity: Tau ² = 0.00; Chi ² = 0.82, df = 2 (P = 0.66); l ² = 0% 80 29.8% 0.91 [0.25, 1.57] Huang 2018 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 [1.99, 3.50] Rah 2017 0.3725 0.188 47 0.4 0.188 47 11.0% -0.15 [-0.55, 0.26] Subtotal (95% CI) 93 94 29.0% 1.15 [-0.48, 2.78] Heterogeneity: Tau ² = 1.97; Chi ² = 44.69, df = 2 (P < 0.00001); l ² = 96% 1.15 [-0.48, 2.78]	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe Study or Subgroup 1.9.1 low dose Amanat 2021 Liu 2017a Liu 2017b Luan 2012	Z = 1.58 (0.02; Chi ^a Z = 3.49 (erences: C Exp Mean 10.65 31.82 16.23	$P = 0.11)$ $P = 0.47, df = 0.0005$ $P = 0.0005$ $hi^{2} = 0.55.$ operimental SD 15.55 34.35075 31.24451	185 = 5 (P =) df = 1 (1 <u>Total</u> 36 33 34 45	= 0.26); = = 0.4 <u>Mean</u> 1.23 7.25 7.25	² = 23% 6). ² = 0% Control 5D 13.49 28.75533 28.75533	Total 36 17 18 49	Weight 10.6% 9.7% 9.9% 11.0%	Std. Mean Difference IV. Random. 95% Cl 0.64 [0.17, 1.11] 0.74 [0.14, 1.35] 0.29 [-0.28, 0.87] 0.67 [0.25, 1.09]	Favours [control] Favours [experimental] Std. Mean Difference
Kang 2015 7.08 8.441 13 3.85 3.752 17 8.8% 0.51 [-0.23, 1.24] Min 2013 9.1 6.681 31 7.8 5.091 32 10.5% 0.22 [-0.28, 0.71] Sun 2017 7.5 6.8 32 6.9 5.5 31 10.5% 0.10 [-0.40, 0.59] Subtotal (95% CI) 76 80 29.8% 0.22 [-0.10, 0.54] Heterogeneity: Tau ² = 0.00; Chi ² = 0.82, df = 2 (P = 0.66); l ² = 0% 80 29.8% 0.21 [-0.10, 0.54] Heterogeneity: Tau ² = 0.00; Chi ² = 0.82, df = 2 (P = 0.66); l ² = 0% 80 29.8% 0.91 [0.25, 1.57] Huang 2018 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 [1.99, 3.50] Rah 2017 0.3725 0.188 47 0.4 0.188 47 11.0% -0.15 [-0.55, 0.26] Subtotal (95% CI) 93 94 29.0% 1.15 [-0.48, 2.78] Heterogeneity: Tau ² = 1.97; Chi ² = 44.69, df = 2 (P < 0.00001); l ² = 96%	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe Study or Subaroup 1.9.1 low dose Amanat 2021 Liu 2017a Liu 2017b Luan 2012 Subtotal (95% CI) Heterogeneity: Tau ² =	Z = 1.58 (0.02; Chi ³ Z = 3.49 (erences: C <u>Exp</u> <u>Mean</u> 10.65 31.82 16.23 5.69 0.00; Chi ³	P = 0.11) ² = 6.47, df P = 0.0005 thi ² = 0.55, t sperimental SD 15.55 34.35075 31.24451 2.91 ² = 1.46, df	185 = 5 (P =) df = 1 (f 36 33 34 45 148 = 3 (P =	= 0.26); = = 0.4 <u>Mean</u> 1.23 7.25 7.25 3.92	² = 23% 6). ² = 0% Control 5D 13.49 28.75533 28.75533 2.33	Total 36 17 18 49	Weight 10.6% 9.7% 9.9% 11.0%	Std. Mean Difference IV. Random. 95% Cl 0.64 [0.17, 1.11] 0.74 [0.14, 1.35] 0.29 [-0.28, 0.87] 0.67 [0.25, 1.09]	Favours [control] Favours [experimental] Std. Mean Difference
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe Study or Subgroup 1.9.1 low dose Amanat 2021 Liu 2017a Liu 2017a Liu 2017b Luan 2012 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect:	Z = 1.58 (0.02; Chi ³ Z = 3.49 (erences: C <u>Exp</u> <u>Mean</u> 10.65 31.82 16.23 5.69 0.00; Chi ³	P = 0.11) ² = 6.47, df P = 0.0005 thi ² = 0.55, t sperimental SD 15.55 34.35075 31.24451 2.91 ² = 1.46, df	185 = 5 (P =) df = 1 (f 36 33 34 45 148 = 3 (P =	= 0.26); = = 0.4 <u>Mean</u> 1.23 7.25 7.25 3.92	² = 23% 6). ² = 0% Control 5D 13.49 28.75533 28.75533 2.33	Total 36 17 18 49	Weight 10.6% 9.7% 9.9% 11.0%	Std. Mean Difference IV. Random. 95% Cl 0.64 [0.17, 1.11] 0.74 [0.14, 1.35] 0.29 [-0.28, 0.87] 0.67 [0.25, 1.09]	Favours [control] Favours [experimental] Std. Mean Difference
Sun 2017 7.5 6.8 32 6.9 5.5 31 10.5% 0.10 [-0.40, 0.59] Subtotal (95% CI) 76 80 29.8% 0.22 [-0.10, 0.54] Heterogeneity: Tau ² = 0.00; Chi ² = 0.82, df = 2 (P = 0.66); l ² = 0% Test for overall effect: Z = 1.37 (P = 0.17) 1.9.3 high dose 0.202 64.526 41.85 19 36.8 8.802 20 9.3% 0.91 [0.25, 1.57] Huang 2018 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 [1.99, 3.50] Rah 2017 0.3725 0.188 47 0.48 47 11.0% -0.15 [-0.55, 0.26] Subtotal (95% CI) 93 94 29.0% 1.15 [-0.48, 2.78] Heterogeneity: Tau ² = 1.97; Chi ² = 44.69, df = 2 (P < 0.00001); l ² = 96%	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for suboroup diffe Study or Subgroup 19.1 low dose Amanat 2021 Liu 2017a Liu 2017a Liu 2017b Luan 2012 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.2 medium dose	Z = 1.58 (0.02; Chi ^a Z = 3.49 (erences: C Exp <u>Mean</u> 10.65 31.82 16.23 5.69 0.00; Chi ^a Z = 4.72 (P = 0.11) = 6.47, df P = 0.0005 hi ² = 0.55, . serimental SD 15.55 34.35075 31.24451 2.91 = 1.46, df P < 0.0000	185 = 5 (P =) df = 1 (1 <u>Total</u> 36 33 34 45 148 = 3 (P = 1)	= 0.26); P = 0.4 <u>Mean</u> 1.23 7.25 7.25 3.92 = 0.69);	l² = 23% 6). l² = 0% Control 13.49 28.75533 28.75533 2.33 l² = 0%	Total 36 17 18 49 120	Weight 10.6% 9.7% 9.9% 11.0% 41.2%	Std. Mean Difference IV. Random. 95% Cl 0.64 [0.17, 1.11] 0.74 [0.14, 1.35] 0.29 [-0.28, 0.87] 0.67 [0.25, 1.09] 0.60 [0.35, 0.85]	Favours [control] Favours [experimental] Std. Mean Difference
Subtotal (95% CI) 76 80 29.8% 0.22 [-0.10, 0.54] Heterogeneity: Tau ² = 0.00; Chi ² = 0.82, df = 2 (P = 0.66); l ² = 0% 76 80 29.8% 0.22 [-0.10, 0.54] Heterogeneity: Tau ² = 0.00; Chi ² = 0.82, df = 2 (P = 0.66); l ² = 0% 76 80 29.8% 0.22 [-0.10, 0.54] Heterogeneity: Tau ² = 1.37 (P = 0.17) 1.9.3 high dose 9.3% 0.91 [0.25, 1.57] Gu 2020 64.526 41.85 19 36.8 8.802 20 9.3% 0.91 [0.25, 1.57] Huang 2018 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 [1.99, 3.50] Rah 2017 0.3725 0.188 47 0.188 47 11.0% -0.15 [-0.55, 0.26] Subtotal (95% CI) 93 94 29.0% 1.15 [-0.48, 2.78]	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe Study or Subgroup 1.9.1 low dose Amanat 2021 Liu 2017a Liu 2017b Luan 2012 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.2 medium dose Kang 2015	Z = 1.58 (0.02; Chi ² Z = 3.49 (erences: C Exp Mean 10.65 31.82 16.23 5.69 0.00; Chi ² Z = 4.72 (7.08	P = 0.11) = 6.47, df P = 0.0005 hi ² = 0.55, i cerimental SD 15.55 34.35075 31.24451 2.91 = 1.46, df P < 0.0000 8.441	185 = 5 (P =) df = 1 (1 <u>Total</u> 36 33 34 45 148 = 3 (P = 1) 13	= 0.26); P = 0.4 Mean 1.23 7.25 3.92 = 0.69); 3.85	l² = 23% 6). l² = 0% Control 13.49 28.75533 2.33 l² = 0% 3.752	Total 36 17 18 49 120 17	Weight 10.6% 9.7% 9.9% 11.0% 41.2% 8.8%	Std. Mean Difference IV. Random. 95% CI 0.64 [0.17, 1.11] 0.74 [0.14, 1.35] 0.29 [-0.28, 0.87] 0.67 [0.25, 1.09] 0.60 [0.35, 0.85] 0.51 [-0.23, 1.24]	Favours [control] Favours [experimental] Std. Mean Difference
Heterogeneity: Tau ² = 0.00; Chi ² = 0.82, df = 2 (P = 0.66); l ² = 0% Fest for overall effect: Z = 1.37 (P = 0.17) 1.9.3 high dose Su 2020 64.526 41.85 19 36.8 8.802 20 9.3% 0.91 [0.25, 1.57] Huang 2018 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 [1.99, 3.50] Rah 2017 0.3725 0.188 47 0.4 0.188 47 11.0% -0.15 [-0.55, 0.26] Subtotal (95% Cl) 93 94 29.0% 1.15 [-0.48, 2.78] Heterogeneity: Tau ² = 1.97; Chi ² = 44.69, df = 2 (P < 0.00001); l ² = 96%	Fotal (95% CI) Heterogeneity: Tau ² = Fest for overall effect: Fest for suboroup diffe Study or Subgroup 1.9.1 low dose Amanat 2021 .iu 2017b .iu 2017b .uan 2012 Subtotal (95% CI) Heterogeneity: Tau ² = Fest for overall effect: 1.9.2 medium dose (ang 2015 Vin 2013	Z = 1.58 (0.02; Chi ² Z = 3.49 (arences: C Exp Mean 10.65 31.82 16.23 5.69 0.00; Chi ² Z = 4.72 (7.08 9.1	$P = 0.11)$ $P = 0.005$ $P = 0.0005$ $P = 0.0005$ $hi^{2} = 0.55.$ berimental SD 15.55 34.35075 31.24451 2.91 P = 1.46, df $P < 0.0000$ 8.441 6.681	185 = 5 (P =) ff = 1 (/ Total 36 33 34 45 148 = 3 (P = 1) 13 31	= 0.26); = 0.4 Mean 1.23 7.25 7.25 3.92 = 0.69); 3.85 7.8	² = 23% 6). ² = 0% Control 28.75533 28.75533 2.33 ² = 0% 3.752 5.091	Total 36 17 18 49 120 17 32	Weight 10.6% 9.7% 9.9% 11.0% 41.2% 8.8% 10.5%	Std. Mean Difference IV. Random, 95% CI 0.64 [0.17, 1.11] 0.74 [0.14, 1.35] 0.29 [-0.28, 0.87] 0.67 [0.25, 1.09] 0.60 [0.35, 0.85] 0.51 [-0.23, 1.24] 0.22 [-0.28, 0.71]	Favours [control] Favours [experimental] Std. Mean Difference
Gu 2020 64.526 41.85 19 36.8 8.802 20 9.3% 0.91 [0.25, 1.57] Huang 2018 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 [1.99, 3.50] Rah 2017 0.3725 0.188 47 0.4 0.188 47 11.0% -0.15 [-0.55, 0.26] Subtotal (95% CI) 93 94 29.0% 1.15 [-0.48, 2.78] Heterogeneity: Tau ² = 1.97; Chi ² = 44.69, df = 2 (P < 0.00001); l ² = 96% 94 29.0% 1.15 [-0.48, 2.78]	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe Study or Subgroup 1.9.1 low dose Amanat 2021 Liu 2017a Liu 2017b Luan 2017 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.2 medium dose Kang 2015 Min 2013 Sun 2017	Z = 1.58 (0.02; Chi ² Z = 3.49 (arences: C Exp Mean 10.65 31.82 16.23 5.69 0.00; Chi ² Z = 4.72 (7.08 9.1	$P = 0.11)$ $P = 0.005$ $P = 0.0005$ $P = 0.0005$ $hi^{2} = 0.55.$ berimental SD 15.55 34.35075 31.24451 2.91 P = 1.46, df $P < 0.0000$ 8.441 6.681	185 = 5 (P =)) iff = 1 (l) Total 36 33 34 45 148 = 3 (P = 1) 13 31 32	= 0.26); = 0.4 Mean 1.23 7.25 7.25 3.92 = 0.69); 3.85 7.8	² = 23% 6). ² = 0% Control 28.75533 28.75533 2.33 ² = 0% 3.752 5.091	Total 36 17 18 49 120 17 32 31	Weight 10.6% 9.7% 9.9% 11.0% 41.2% 8.8% 10.5%	Std. Mean Difference IV. Random. 95% Cl 0.64 [0.17, 1.11] 0.74 [0.14, 1.35] 0.29 [-0.28, 0.87] 0.67 [0.25, 1.09] 0.60 [0.35, 0.85] 0.51 [-0.23, 1.24] 0.22 [-0.28, 0.71] 0.10 [-0.40, 0.59]	Favours [control] Favours [experimental] Std. Mean Difference
Gu 2020 64.526 41.85 19 36.8 8.802 20 9.3% 0.91 [0.25, 1.57] Huang 2018 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 [1.99, 3.50] Rah 2017 0.3725 0.188 47 0.4 0.188 47 11.0% -0.15 [-0.55, 0.26] Subtotal (95% Cl) 93 94 29.0% 1.15 [-0.48, 2.78] Heterogeneity: Tau ² = 1.97; Chi ² = 44.69, df = 2 (P < 0.00001); l ² = 96% 94 29.0% 1.15 [-0.48, 2.78]	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe Study or Subaroup 1.9.1 low dose Amanat 2021 Liu 2017a Liu 2017b Luan 2012 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.2 medium dose Kang 2015 Min 2013 Sun 2017 Subtotal (95% CI) Heterogeneity: Tau ² =	Z = 1.58 (0.02; Chi ³ Z = 3.49 (arences: C Exp Mean 10.65 31.82 16.23 5.69 0.00; Chi ³ Z = 4.72 (7.08 9.1 7.5 0.00; Chi ³	$P = 0.11)$ $^{2} = 6.47, df$ $P = 0.0005$ $hi^{2} = 0.55.$ berimental SD 15.55 34.35075 31.24451 2.91 $^{2} = 1.46, df$ $P < 0.0000$ 8.441 6.681 6.8 $^{2} = 0.82, df$	1855 (P =)) (Total 36 33 34 455 148 = 3 (P = 1) 13 31 32 76	 □ = 0.26); □ = 0.4 Mean 1.23 7.25 7.25 3.92 3.92 a.85 7.8 6.9 	I ² = 23% 6). I ² = 0% Control 13.49 28.75533 2.33 I ² = 0% 3.752 5.091 5.5	Total 36 17 18 49 120 17 32 31	Weight 10.6% 9.7% 9.9% 11.0% 41.2% 8.8% 10.5%	Std. Mean Difference IV. Random. 95% Cl 0.64 [0.17, 1.11] 0.74 [0.14, 1.35] 0.29 [-0.28, 0.87] 0.67 [0.25, 1.09] 0.60 [0.35, 0.85] 0.51 [-0.23, 1.24] 0.22 [-0.28, 0.71] 0.10 [-0.40, 0.59]	Favours [control] Favours [experimental] Std. Mean Difference
Huang 2018 12.66 3.429 27 4.81 2.026 27 8.6% 2.75 [1.99, 3.50] Rah 2017 0.3725 0.188 47 0.4 0.188 47 11.0% -0.15 [-0.55, 0.26] Subtotal (95% CI) 93 94 29.0% 1.15 [-0.48, 2.78] Heterogeneity: Tau ² = 1.97; Chi ² = 44.69, df = 2 (P < 0.00001); l ² = 96% 94 29.0% 1.25 [-0.48, 2.78]	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for suboroup diffe Study or Subgroup 1.9.1 low dose Amanat 2021 Liu 2017a Liu 2017a Liu 2017b Luan 2012 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.2 medium dose Kang 2015 Min 2013 Sun 2017 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect:	Z = 1.58 (0.02; Chi ³ Z = 3.49 (arences: C Exp Mean 10.65 31.82 16.23 5.69 0.00; Chi ³ Z = 4.72 (7.08 9.1 7.5 0.00; Chi ³	$P = 0.11)$ $^{2} = 6.47, df$ $P = 0.0005$ $hi^{2} = 0.55.$ berimental SD 15.55 34.35075 31.24451 2.91 $^{2} = 1.46, df$ $P < 0.0000$ 8.441 6.681 6.8 $^{2} = 0.82, df$	1855 (P =)) (Total 36 33 34 455 148 = 3 (P = 1) 13 31 32 76	 □ = 0.26); □ = 0.4 Mean 1.23 7.25 7.25 3.92 3.92 a.85 7.8 6.9 	I ² = 23% 6). I ² = 0% Control 13.49 28.75533 2.33 I ² = 0% 3.752 5.091 5.5	Total 36 17 18 49 120 17 32 31	Weight 10.6% 9.7% 9.9% 11.0% 41.2% 8.8% 10.5%	Std. Mean Difference IV. Random. 95% Cl 0.64 [0.17, 1.11] 0.74 [0.14, 1.35] 0.29 [-0.28, 0.87] 0.67 [0.25, 1.09] 0.60 [0.35, 0.85] 0.51 [-0.23, 1.24] 0.22 [-0.28, 0.71] 0.10 [-0.40, 0.59]	Favours [control] Favours [experimental] Std. Mean Difference
Rah 2017 0.3725 0.188 47 0.4 0.188 47 11.0% -0.15 [-0.55, 0.26] Subtotal (95% CI) 93 94 29.0% 1.15 [-0.48, 2.78] Heterogeneity: Tau ² = 1.97; Chi ² = 44.69, df = 2 (P < 0.00001); l ² = 96% 96% 1.15 [-0.48, 2.78]	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe Study or Subaroup 1.9.1 low dose Amanat 2021 Liu 2017a Liu 2017b Luan 2012 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.2 medium dose Kang 2015 Min 2013 Sub 2013 Sub 2017 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.3 high dose	Z = 1.58 (0.02; Chi ² Z = 3.49 (perces: C Exp Mean 10.65 31.82 16.23 5.69 0.00; Chi ² Z = 4.72 (7.08 9.1 7.5 0.00; Chi ² Z = 1.37 ($P = 0.11)$ $P = 0.005$ $hi^{2} = 0.55$ $rerimental SD$ 15.55 34.35075 31.24451 2.91 $P < 0.0000$ 8.441 6.681 6.8 $P = 0.82$ $dF = 0.82$ $dF = 0.17$	185 = 5 (P =) df = 1 (l) Total 36 33 34 45 148 = 3 (P = 1) 13 31 32 76 = 2 (P =	 = 0.26); P = 0.4 Mean 1.23 7.25 7.25 3.92 = 0.69); 3.85 7.8 6.9 = 0.66); 	$ ^2 = 23\%$ 6). $ ^2 = 0\%$ Control 13.49 28.75533 2.33 $ ^2 = 0\%$ 3.752 5.091 5.5 $ ^2 = 0\%$	Total 36 17 18 49 120 17 32 31 80	Weight 10.6% 9.7% 9.9% 11.0% 41.2% 8.8% 10.5% 29.8%	Std. Mean Difference IV. Random, 95% CI 0.64 [0.17, 1.11] 0.74 [0.14, 1.35] 0.29 [-0.28, 0.87] 0.67 [0.25, 1.09] 0.60 [0.35, 0.85] 0.51 [-0.23, 1.24] 0.22 [-0.28, 0.71] 0.10 [-0.40, 0.59] 0.22 [-0.10, 0.54]	Favours [control] Favours [experimental] Std. Mean Difference
Subtotal (95% Cl) 93 94 29.0% 1.15 [-0.48, 2.78] Heterogeneity: Tau ² = 1.97; Chi ² = 44.69, df = 2 (P < 0.00001); l ² = 96% 96% 96% 96%	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe Study or Subaroup 1.9.1 low dose Amanat 2021 Liu 2017a Liu 2017b Luan 2012 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.2 medium dose Kang 2015 Min 2013 Sun 2017 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.3 high dose Gu 2020	Z = 1.58 (0.02; Chi ² Z = 3.49 (arences: C Exp Mean 10.65 31.82 16.23 5.69 0.00; Chi ² Z = 4.72 (7.08 9.1 7.5 0.00; Chi ² Z = 1.37 (64.526	P = 0.11) $P = 0.005$ $P = 0.0005$ $P = 0.0005$ SD 15.55 34.35075 31.24451 2.91 $P < 0.0000$ 8.441 6.681 6.8 $P < 0.000$ 8.441 6.681 6.8 $P = 0.17)$ 41.85	185 (P =))f = 1 (() Total 36 33 34 4 48 = 3 (P = 1) 13 31 31 31 32 76 = 2 (P =	 ⇒ = 0.26); ⇒ = 0.4 Mean 1.23 7.25 7.25 3.92 3.85 7.8 6.9 3.868 36.8 	$ ^2 = 23\%$ 6). $ ^2 = 0\%$ Control 31.49 28.75533 2.33 $ ^2 = 0\%$ 3.752 5.091 5.5 $ ^2 = 0\%$ 8.802	Total 36 17 18 49 120 17 32 31 80 20	Weight 10.6% 9.7% 9.9% 11.0% 41.2% 8.8% 10.5% 10.5% 29.8% 9.3%	Std. Mean Difference IV. Random, 95% CI 0.64 [0.17, 1.11] 0.74 [0.14, 1.35] 0.29 [-0.28, 0.87] 0.67 [0.25, 1.09] 0.60 [0.35, 0.85] 0.51 [-0.23, 1.24] 0.22 [-0.28, 0.71] 0.10 [-0.40, 0.59] 0.22 [-0.10, 0.54] 0.91 [0.25, 1.57]	Favours [control] Favours [experimental] Std. Mean Difference
Heterogeneity: Tau ² = 1.97; Chi ² = 44.69, df = 2 (P < 0.00001); l ² = 96%	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe Study or Subaroup diffe Study or Subaroup Liu 2017a Liu 2017a Liu 2017b Luan 2012 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.2 medium dose Kang 2015 Min 2013 Sun 2017 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.3 high dose Gu 2020 Huang 2018	Z = 1.58 (0.02; Chi ² Z = 3.49 (grences: C Exp Mean 10.65 31.82 16.23 5.69 0.00; Chi ² Z = 4.72 (7.08 9.1 7.5 0.00; Chi ² Z = 1.37 (64.526 12.66	P = 0.11) $P = 0.005$ $P = 0.0005$ $P = 0.0005$ $P = 0.005$ SD 15.55 34.35075 31.24451 2.91 $P = 0.46, df$ $P < 0.0000$ 8.441 6.681 6.81 6.82 $P = 0.17)$ 41.85 3.429	185 = 5 (P =) df = 1 (<i>l</i>) Total 36 33 34 45 45 45 45 45 13 31 31 31 32 76 6 = 2 (P = - - - - - - - - - - - - - - - - - -	 = 0.26); > = 0.4 Mean 1.23 7.25 7.25 3.92 = 0.69); 3.85 7.8 6.9 = 0.66); 36.8 4.81 	$ ^2 = 23\%$ 6). $ ^2 = 0\%$ Control SD 13.49 28.75533 2.33 $ ^2 = 0\%$ 3.752 5.091 5.5 $ ^2 = 0\%$ 8.802 2.026	Total 36 17 18 49 120 17 32 31 80 20 27	Weight 10.6% 9.9% 11.0% 41.2% 8.8% 10.5% 10.5% 29.8% 9.3% 8.6%	Std. Mean Difference IV. Random, 95% CI 0.64 [0.17, 1.11] 0.74 [0.14, 1.35] 0.29 [-0.28, 0.87] 0.67 [0.25, 1.09] 0.60 [0.35, 0.85] 0.51 [-0.23, 1.24] 0.22 [-0.28, 0.71] 0.10 [-0.40, 0.59] 0.22 [-0.10, 0.54] 0.91 [0.25, 1.57] 2.75 [1.99, 3.50]	Favours [control] Favours [experimental] Std. Mean Difference
	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for suboroup diffe Study or Subgroup Liu 2017a Liu 2017a Liu 2017b Liu 2017b Liu 2017b Liu 2017b Liu 2017b Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.2 medium dose Kang 2015 Min 2013 Sun 2017 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.3 high dose Gu 2020 Huang 2018 Rah 2017	Z = 1.58 (0.02; Chi ² Z = 3.49 (grences: C Exp Mean 10.65 31.82 16.23 5.69 0.00; Chi ² Z = 4.72 (7.08 9.1 7.5 0.00; Chi ² Z = 1.37 (64.526 12.66	P = 0.11) $P = 0.005$ $P = 0.0005$ $P = 0.0005$ $P = 0.005$ SD 15.55 34.35075 31.24451 2.91 $P = 0.46, df$ $P < 0.0000$ 8.441 6.681 6.81 6.82 $P = 0.17)$ 41.85 3.429	1855 (P =)) ff = 1 (l Total 36 33 45 148 = 3 (P = 1) 13 31 32 76 = 2 (P = 19 27 47	 = 0.26); > = 0.4 Mean 1.23 7.25 7.25 3.92 = 0.69); 3.85 7.8 6.9 = 0.66); 36.8 4.81 	$ ^2 = 23\%$ 6). $ ^2 = 0\%$ Control SD 13.49 28.75533 2.33 $ ^2 = 0\%$ 3.752 5.091 5.5 $ ^2 = 0\%$ 8.802 2.026	Total 36 17 18 49 120 17 32 31 80 20 27 47	Weight 10.6% 9.9% 11.0% 41.2% 8.8% 10.5% 10.5% 29.8% 9.3% 8.6% 11.0%	Std. Mean Difference IV. Random. 95% Cl 0.64 [0.17, 1.11] 0.74 [0.14, 1.35] 0.29 [-0.28, 0.87] 0.67 [0.25, 1.09] 0.60 [0.35, 0.85] 0.51 [-0.23, 1.24] 0.22 [-0.28, 0.71] 0.10 [-0.40, 0.59] 0.22 [-0.10, 0.54] 0.91 [0.25, 1.57] 2.75 [1.99, 3.50] -0.15 [-0.55, 0.26]	Favours [control] Favours [experimental] Std. Mean Difference
	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe Study or Subgroup 1.9.1 low dose Amanat 2021 Liu 2017a Liu 2017b Luan 2012 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.2 medium dose Kang 2015 Sub 2017 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.3 high dose Gu 2020 Huang 2018 Rah 2017 Subtotal (95% CI) Heterogeneity: Tau ² =	Z = 1.58 (0.02; Chi ² Z = 3.49 (arences: C Exp Mean 10.65 31.82 16.23 5.69 0.00; Chi ² Z = 4.72 (7.08 9.1 7.5 0.00; Chi ² Z = 1.37 (64.526 12.66 0.3725 1.97; Chi ²	P = 0.11) $P = 0.11)$ $P = 0.0005$ $P = 0.0005$ SD 15.55 34.35075 31.24451 2.91 $P < 0.0000$ 8.441 6.681 6.8 $P < 0.0000$ 8.441 6.681 6.8 $P < 0.0000$ 8.441	1855 (P =)) df = 1 (l) Total 363 34 45 138 (P = 1) 13 31 32 76 = 2 (P = 19 277 76 79 3	 □ = 0.26); □ = 0.4 Mean 1.23 7.25 3.92 = 0.69); 3.85 7.8 6.9 = 0.66); 36.8 4.81 0.4 	² = 23% 6). ² = 0% Control 28.75533 2.33 ² = 0% 3.752 5.091 5.5 ² = 0% 8.802 2.026 0.188	Total 36 17 18 49 120 17 32 31 80 20 27 47 94	Weight 10.6% 9.9% 11.0% 41.2% 8.8% 10.5% 10.5% 29.8% 9.3% 8.6% 11.0%	Std. Mean Difference IV. Random. 95% Cl 0.64 [0.17, 1.11] 0.74 [0.14, 1.35] 0.29 [-0.28, 0.87] 0.67 [0.25, 1.09] 0.60 [0.35, 0.85] 0.51 [-0.23, 1.24] 0.22 [-0.28, 0.71] 0.10 [-0.40, 0.59] 0.22 [-0.10, 0.54] 0.91 [0.25, 1.57] 2.75 [1.99, 3.50] -0.15 [-0.55, 0.26]	Favours [control] Favours [experimental] Std. Mean Difference
	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for suboroup diffe Study or Subgroup 1.9.1 low dose Amanat 2021 Liu 2017a Liu 2017a Liu 2017b Liu 2017b Liu 2017b Liu 2017b Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.2 medium dose Kang 2015 Min 2013 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.3 high dose Gu 2020 Huang 2018 Rah 2017 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect:	Z = 1.58 (0.02; Chi ² Z = 3.49 (arences: C Exp Mean 10.65 31.82 16.23 5.69 0.00; Chi ² Z = 4.72 (7.08 9.1 7.5 0.00; Chi ² Z = 1.37 (64.526 12.66 0.3725 1.97; Chi ²	P = 0.11) $P = 0.11)$ $P = 0.0005$ $P = 0.0005$ SD 15.55 34.35075 31.24451 2.91 $P < 0.0000$ 8.441 6.681 6.8 $P < 0.0000$ 8.441 6.681 6.8 $P < 0.0000$ 8.441	1855 (P =)) ff = 1 (l Total 36 33 45 148 = 3 (P = 1) 13 31 32 76 = 2 (P = 19 27 47 93 37 = 2 (P	 □ = 0.26); □ = 0.4 Mean 1.23 7.25 3.92 = 0.69); 3.85 7.8 6.9 = 0.66); 36.8 4.81 0.4 	² = 23% 6). ² = 0% Control 28.75533 2.33 ² = 0% 3.752 5.091 5.5 ² = 0% 8.802 2.026 0.188	Total 36 17 18 49 120 17 32 31 80 27 24 7 94	Weight 10.6% 9.9% 11.0% 41.2% 8.8% 10.5% 29.8% 9.3% 8.6% 11.0% 29.0%	Std. Mean Difference IV. Random, 95% CI 0.64 [0.17, 1.11] 0.74 [0.14, 1.35] 0.29 [-0.28, 0.87] 0.67 [0.25, 1.09] 0.60 [0.35, 0.85] 0.51 [-0.23, 1.24] 0.22 [-0.28, 0.71] 0.10 [-0.40, 0.59] 0.22 [-0.10, 0.54] 0.91 [0.25, 1.57] 2.75 [1.99, 3.50] -0.15 [-0.55, 0.26] 1.15 [-0.48, 2.78]	Favours [control] Favours [experimental] Std. Mean Difference
Heterogeneity: Tau ² = 0.34; Chi ² = 50.92, df = 9 (P < 0.00001); l ² = 82% Test for overall effect: Z = 3.04 (P = 0.002)	Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe Study or Subaroup 1.9.1 low dose Amanat 2021 Liu 2017a Liu 2017b Luan 2012 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.2 medium dose Kang 2015 Min 2013 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.3 high dose Gu 2020 Huang 2018 Rah 2017 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.9.3 high dose Gu 2020 Huang 2018 Rah 2017 Subtotal (95% CI)	Z = 1.58 (0.02; Chi ³ Z = 3.49 (arences: C Exp Mean 10.65 31.82 16.23 5.69 0.00; Chi ³ Z = 4.72 (7.08 9.1 7.5 0.00; Chi ³ Z = 1.37 (64.526 12.66 0.3725 1.97; Chi ³ Z = 1.38 (P = 0.11) $P = 0.10$ $P = 0.005$ $P = 0.0005$ SD 15.55 34.35075 31.24451 2.91 $P = 0.4000$ 8.441 6.681 6.8 $P = 0.17$ 41.85 3.429 0.188 $P = 0.17$	1855 (P =)))))))))))))	 = 0.26); → = 0.4 Mean 1.23 7.25 3.92 3.85 7.8 6.9 36.8 4.81 0.4 < 0.00 	² = 23% 6). ² = 0% Control 28.75533 28.75533 2.33 ² = 0% 3.752 5.091 5.5 ² = 0% 8.802 2.026 0.188 001); ² = 96	Total 36 17 18 49 120 17 32 31 80 20 27 4 94	Weight 10.6% 9.9% 11.0% 41.2% 8.8% 10.5% 29.8% 9.3% 8.6% 11.0% 29.0%	Std. Mean Difference IV. Random. 95% Cl 0.64 [0.17, 1.11] 0.74 [0.14, 1.35] 0.29 [-0.28, 0.87] 0.67 [0.25, 1.09] 0.60 [0.35, 0.85] 0.51 [-0.23, 1.24] 0.22 [-0.28, 0.71] 0.10 [-0.40, 0.59] 0.22 [-0.10, 0.54] 0.91 [0.25, 1.57] 2.75 [1.99, 3.50] -0.15 [-0.55, 0.26]	Favours [control] Favours [experimental] Std. Mean Difference

FIGURE 6

Forest plot of subgroup in GMFM. Forest plot demonstrating the effect of stem cells compared with controls in subgroup of (A) stem cells types, (B) administration route and (C) dose. 9 years in the 9 studies. Taking 4 years old as the dividing line, these studies were divided into two groups for subgroup analysis according to the average age of patients with stem cell infusion (Supplementary Material S5B). The results showed that GMFM improved significantly after SCT in the 1–4 years (SMD: 0.45; 95%CI [0.16, 0.74]; p = 0.002; heterogeneity test p = 0.22; $I^2 = 31\%$) and 4–9 years group (SMD: 0.56; 95%CI [0.25, 0.88]; p = 0.0004; heterogeneity test p = 0.52; $I^2 = 0\%$). There was no significant difference between the two subgroups (heterogeneity test p = 0.61; $I^2 = 0\%$).

3.4.4 Safety indicator

To explore the safety of SCT, we conducted a metaanalysis of AE. Studies that did not report AE in the control group were not included in this analysis. The number of AE of different types was reported in each study, and the total event frequency was larger than the sample size, which made direct data consolidation impractical. We performed a subgroup analysis of the same events (fever, vomiting, upper respiratory infection, constipation and urticaria) reported in each study to assess safety (Figure 7). Pooled analysis indicated that the overall effect was not statistically significant, and there was no difference in the incidence of AE between SCT and the control group (RR = 1.13; 95% CI = [0.90, 1.42]; *p* = 0.30; heterogeneity test p = 0.67; $I^2 = 0\%$). Although there was difference in the vomiting group (RR = 2.56; 95% CI = [1.09,6.02]; p = 0.03; heterogeneity test p = 0.91; $I^2 = 0\%$), all studies indicated that there were no adverse consequences after symptomatic treatment or spontaneous remission.

3.5 Descriptive analysis

3.5.1 magnetic resonance imaging and diffusion tensor imaging

Amanat et al. (2021) and Huang et al. (2018) suggested no significant improvements in the Magnetic Resonance Imaging (MRI) of participants were observed compared to the baseline. However, the Diffusion Tensor Imaging (DTI) analysis showed that mean fractional anisotropy (FA) increased significantly in the SCT group and was statistically higher than the control group according to two studies (Min et al., 2013; Amanat et al., 2021). In addition, Amanat et al. (2021) suggested the mean diffusivity (MD) decreased significantly in the experimental group and was statistically lower than the control group. And Min et al. (2013) revealed changes in FA of the spinothalamic tract in the right posterior lower pons, with the umbilical cord blood (UCB) group showing greater increments than did the other groups. On the contrary, in the MRI-DTI scans of (Rah et al., 2017), although there was a trend of increasing FA values and decreasing apparent diffusion coefficient (ADC) values over time, these trends were not statistically significant.

Sun et al. (2017) performed whole brain connectome analysis based on MRI diffusion-weighted images from all directions, which suggested patients who received total nucleated cell count (TNCC) > 2 × 10⁷/kg demonstrated a statistically significant greater increase in normalized whole brain connectivity 1 year after treatment than children who received lower doses. In the sensorimotor network, nodes with significant increases in connectivity that correlated with improvement in GMFM-66 scores included the pre- and post-central gyri, basal ganglia, and brain stem.

3.5.2 Positron emission tomography/computed tomography

Both Gu et al. (2020) and Kang et al. (2015) showed significant improvements in brain activity. Interestingly, Kang et al. (2015) observed in the UCB group, increased activity in multiple cortical areas of the frontal and parietal lobes was accompanied by a significant decrease in bilateral white matter activity of the occipital and temporal lobes. The opposite was true for the control group. The results of (Rah et al., 2017) were consistent with the trend of DTI detection, although they observed metabolic changes to the cerebellum, thalamus and cerebral cortex in the brain PET-CT, there were no significant differences in the incidence of metabolic changes between the mobilized peripheral blood mononuclear cells (mPBMC) and placebo groups.

3.5.3 Biochemical parameters

Kang et al. (2015) examined the patient's biochemical parameters and performed a regression analysis with the GMFM score, suggesting a meaningful perspective that increases in PTX3 from baseline to 1-day post-treatment were correlated with improvements in GMPM at 1-month posttreatment, increases in IL-8 level from baseline to 12 days post-treatment were correlated with improvements in GMFM at 6 months post-treatment.

4 Discussion

There are limited treatments available for CP, and stem cells show promising therapeutic potential, with mounting clinical studies data. From 9 studies identified, this meta-analysis showed that stem cell administration significantly improved motor outcomes (GMFM, CFA, GMPM and WeeFIM). Besides, there was no statistical difference in the incidence of AE between the stem cell treatment group and the control group, which suggested that CP is safe to be treated with stem cells. Although SCT showed favorable results for CP patients, we can glimpse from the included studies where future CP stem cell therapies still need to be explored.

In clinical trials of Cochrane's (www.cochranelibrary.com) registered stem cell treatment for CP (Supplementary Material

	Experim	ental	Contr	ol		Risk Ratio	Risk Ratio
tudy or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
.1.1 Fever							
Amanat 2021	2	36	0	36	0.5%	5.00 [0.25, 100.63]	
Gu 2020	7	19	4	20	4.3%	1.84 [0.64, 5.30]	+
ang 2015	6	18	7	18	7.6%	0.86 [0.36, 2.05]	
1in 2013	12	35	8	34	8.9%	1.46 [0.68, 3.12]	+
Sun 2017	0	32	1	0	2.270	Not estimable	
ubtotal (95% CI)	Ŭ	140		108	21.3%	1.41 [0.86, 2.31]	•
otal events	27		20				
leterogeneity: Chi ² = est for overall effect:	2.18, df = 3		53); I² = 0	%			
.1.2 Vomiting							
manat 2021	1	36	0	36	0.5%	3.00 [0.13, 71.28]	
Gu 2020	5	19	3	20	3.2%	1.75 [0.48, 6.35]	-
ang 2015	4	18	1	18	3.2 <i>%</i> 1.1%	4.00 [0.49, 32.39]	-
ang 2013 1in 2013	4 6	35	2	34	2.2%	2.91 [0.63, 13.45]	
	0	35 108	Z	108	Z.2% 7.0%	2.56 [1.09, 6.02]	
ubtotal (95% CI)	10	100	~	100	1.070	2.00 [1.09, 0.02]	-
otal events	16	·	6	•			
leterogeneity: Chi ² =	,	·	/ .	%			
est for overall effect:	Z = 2.16 (F	P = 0.03)					
.1.3 Upper respirato	ry infectio	n					
Gu 2020	10	19	14	20	14.9%	0.75 [0.45, 1.26]	
luang 2018	10	20	8	18	9.2%	1.13 [0.57, 2.21]	- -
ang 2015	6	18	4	18	4.4%	1.50 [0.51, 4.43]	
lin 2013	18	35	21	34	23.3%	0.83 [0.55, 1.26]	
Subtotal (95% CI)	10	92	21	90	51.7%	0.92 [0.69, 1.22]	
otal events	44	-	47		0.1170	cica [cico, iima]	ľ
leterogeneity: Chi ² = est for overall effect:							
.1.4 Constipation		10	~		0.00/		
Gu 2020	1	19	3	20	3.2%	0.35 [0.04, 3.09]	
luang 2018	2	20	2	18	2.3%	0.90 [0.14, 5.74]	
ang 2015	1	18	0	18	0.5%	3.00 [0.13, 69.09]	
/in 2013	5	35	5	34	5.5%	0.97 [0.31, 3.06]	
ubtotal (95% CI)		92		90	11.6%	0.88 [0.38, 2.02]	
otal events	9		10				
leterogeneity: Chi ² = est for overall effect:				%			
.1.5 Urticaria							
uang 2018	0	20	1	18	1.7%	0.30 [0.01, 6.97]	
ang 2015	4	18	2	18	2.2%	2.00 [0.42, 9.58]	-+
1in 2013	2	35	4	34	4.4%	0.49 [0.10, 2.48]	
Subtotal (95% CI)	-	73		70	8.3%	0.84 [0.31, 2.27]	
otal events	6	. 5	7		2.0,0		
leterogeneity: $Chi^2 = \frac{1}{2}$	2.02, df = 2	•	36); l² = 1	%			
otal (95% CI)		505		466	100.0%	1.13 [0.90, 1.42]	•
otal events	102		90			_	
leterogeneity: Chi ² = est for overall effect: est for subaroup diffe	14.82, df = Z = 1.04 (F	e = 0.30)	0.67); l² =		5). I² = 40	9%	0.01 0.1 1 10 100 Favours [control] Favours [experimen

S6), the cells used frequently were derived from the umbilical cord and bone marrow, and trials using umbilical cord blood mesenchymal stem cell (UCMSC) as an intervention were the most numerous. This may be related to the availability of umbilical cord and the low immunogenicity (Chamberlain et al., 2007) of MSC. Comparatively, these factors are only a part of the selection of treatment that should be considered, more important is the treatment efficacy. Subgroup analysis of GMFM showed that MSC had a more significant therapeutic effect on CP compared with UBC, which may guide the selection of stem cells for clinical application of SCT in CP. Nevertheless, there are still many sources of MSC, and it is not known whether this might affect the efficacy or not. In addition, there are studies on the differentiation of MSC into neural progenitor cells in vitro and infusion therapy (Luan et al., 2012), which also provides a new direction for SCT. Therefore, a large number of experiments are


still needed to screen specific cell types for CP therapy. Excitingly, a new generation of stem cell therapies, including Exosomes and genome-edited stem cells, is emerging, which may make the potential of stem cell-based therapies more apparent. Exosomes, a signaling molecule, have particular advantages as a new therapy. It not only has the same function as stem cells, but also has a more stable membrane structure than stem cells. Compared with whole-cell therapy, exosomes are well tolerated and have low immunogenicity (Tang et al., 2021). Using gene therapy and gene editing technology, it is possible to create more functional, specific and reactive stem cell derivatives based on traditional stem cells. For example, stem cells that overexpress neurotrophic factors, anti-inflammatory cytokines, or angiogenic factors can promote the healing and recovery of tissues damaged by injury or disease (Kimbrel and Lanza, 2020). In addition, the application of biomaterials in stem cell therapies can create spaces for cells to contact host tissues, establish platforms for delivery of various growth factors and seed cells, and provide better microenvironments for surviving cells (Li et al., 2022). These could make stem cell-based therapies more promising and offer more treatment options for complex neurological diseases.

The etiology of CP is heterogeneous (Jantzie et al., 2018; Shariati et al., 2021), resulting in children with CP having different symptoms. There are many classifications of CP, the most commonly used being the one proposed by Ingram in 1955 (Ingram, 1955), which includes the following clinical types: hemiplegia, double hemiplegia, diplegia, ataxia diplegia, Ataxia, and dyskinesia. It is necessary to identify the type of CP that best responds to SCT. We performed a subgroup analysis of studies in which all patients had spastic CP and studies in which subjects were composed of multiple CP types. The results showed that SCT improved GMFM scores in both subgroups, and since there was no difference between groups (subgroup differences p = 0.61; $I^2 = 0\%$), we could not identify which type of CP that was more sensitive to SCT.

Most children with CP are accompanied by one or more of the following symptoms (Novak et al., 2012): pain, intellectual disability, walking difficulty, dysphonia, epilepsy, bladder control problems, sleep disorder, blind or dysphagia. These secondary symptoms may worsen over time, limiting the effectiveness of treatment. Therefore, in CP rehabilitation, early intervention is important to optimize infant motor and cognitive plasticity (Novak et al., 2017). So, is it also better to inject stem cells sooner rather than later? Rosenblum et al. (2012) suggested that three days after hypoxia-ischemia in mice was the optimal time for NSC arterial transplantation. Obviously and regrettably, it is not clinically possible to achieve such rapid diagnosis and cell transplantation. We divided the study into two subgroups of 1-4 and 4-9 years old according to age. The results showed that there was no difference between the two groups, which may be related to the small age range included in the study. Nevertheless, the effect of age at intervention on the outcome of SCT should be determined before SCT is widely used.

Subgroup analysis with a random-effects model showed that SCT significantly increased GMFM scores in 3, 6 and 12 months, compared with the control group in CP (Figure 5). However, GMFM scores exhibited no differences at 1 month. This may be related to the limitations of the evaluation tools. Hielkema (Hielkema et al., 2013) suggested the GMFM-66 differentiated less at lower-ability levels than at higher-ability levels. The GMFM-88 demonstrated flattening of the developmental curve when infants had developed more motor abilities. Longitudinal use of the GMFM in infancy was hampered by age and function-specific limitations. This may suggest that more sensitive to post-treatment assessment of CP need to be developed based on different developmental stages of CP patients.

Stem cell plays the therapeutic role mainly through the direct into differentiation target cells under a specific microenvironment, subsequently, replacing the damaged or missing cells (Maroof et al., 2013). Meanwhile, exogenous stem cells could migrate to the damaged site and activate endogenous stem cells in situ differentiating into target cells along with regulating the niche by paracrine secretion (Siniscalco et al., 2013; Segal-Gavish et al., 2016; Perets et al., 2017). The migration and homing of stem cells are influenced by multiple factors such as number of cells and administration (Sohni and Verfaillie, 2013). Unfortunately, there is no standard dose and delivery method protocol for SCT on CP. In included studies, the dose of cell infusion varied, with the lowest being 4×10^6 /kg and the highest being 5.2×10^8 /kg. Sun et al. (2017) observed no difference in GMFM-66 scores between the UCB and placebo groups. However, his exploratory analysis showed that subjects who received a TNCC >2 \times 10⁷/kg improved a median of 4.3 points greater than expected, and this change was statistically different from that observed in subjects who received $\langle 2 \times 10^7/\text{kg}$ or placebo. Besides, Kang et al. (2015) showed participants who received cells more than the 5.46 \times 10⁷/kg showed greater improvements in BSID-II motor raw score than those who received less cells. The two researchers' data seem



to suggest that the higher the dose, the better the treatment. Surprisingly, we expanded the dose range by combining the included studies, subsequent subgroup analysis showed that SCT significantly increased GMFM scores in low dose (4×10⁶–3 × 10^{7} /kg) (SMD = 0.60, 95% CI = 0.35–0.85, p < 0.00,001), while the medium-dose (3-9 \times 10⁷/kg) and high-dose (9 \times 10⁷-5.2 \times 108/kg) groups did not differ from the control group. This suggested that higher cell doses did not confer the desired therapeutic effect. In addition, it has been reported that there is a risk of cell clumping resulting in embolism at high cell doses (Heng et al., 2008). Therefore, in order to achieve the best therapeutic effect, the optimal dose range needs to be determined, and our current conclusion is 4×10^6 – 3×10^7 /kg. On the other hand, subgroup analysis of administration route showed that GMFM score improvement was more significant in the intrathecal injection group, while there was no significant difference between the intravenous infusion group and the control group. Intravenous infusion of cells limits therapeutic effects, as cells might be trapped in organs such as the lung, liver, or kidney after infusion, reducing the number of cells that homing a specific site (Peng et al., 2020; Nguyen et al., 2021). Nevertheless, our conclusions are based on the treatment outcomes of different stem cells, so more double-blind randomized controlled trials with cell dose and administration as independent variables should be needed in the future.

The imaging tests described above may be a new direction in the assessment of CP, which can be more sensitive to the improved activity of brain regions at the root of CP, rather than just changes in motor function. Even though Amanat et al. (2021) and Huang et al. (2018) did not observe changes in patients' brains in MRI, their study and Min et al. (2013) showed improvement in FA using DTI technology. Gu et al. (2020). and Kang et al. (2015) observed improvements in metabolic activity of patients' brains using PET-CT. It should not be ignored that long-term repeated imaging examinations may bring harm to patients with CP. Therefore, it is worth trying as Huang et al. (2018) links blood biochemical indicators with the prognosis of CP, but the results still need to be verified by a large number of studies. Early brain injury impacts concomitantly on motor and cognitive development and function (Hielkema and Hadders-Algra, 2016), yet few studies describe the cognitive functioning in this population. Further, cognitive impacts may be realized only later in childhood due to the protracted nature of cognitive development, relative to motor skill development (Hoare et al., 2018). Although the motor function related scale score of the stem cell treatment group was higher than the control group, there was no difference in the BSID score of the two groups, which may indicate that SCT may have a limited therapeutic effect on cognition, but the results should be interpreted with caution due to high heterogeneity.

Although we evaluated the safety and efficacy of SCT for CP and discussed the details that need to be improved in the treatment regimen, the study still had limitations. We evaluated and analyzed the heterogeneity of included outcomes and found that there was a high heterogeneity in GMFM scores. Sensitivity analysis indicated that the studies of Huang et al. (2018) and Rah et al. (2017) resulted in high heterogeneity. The heterogeneity of former may be caused by the data processing method which analyzed the scores at each follow-up stage accounted for the total score of the scale. The total number of Rah et al. (2017) participants was 57, but only 47 were involved in outcome analysis. The lack of available data may have led to the bias of the results, resulting in heterogeneity. Thankfully, if we exclude the two study, heterogeneity will return to $I^2 = 5\%$ and the pooled results are consistent with the previous trend. In this paper, subgroup analysis was performed to discuss the factors that may influence the SCT for CP, such as cell type, dose, route of administration, type of CP, time point of follow-up, and age of intervention. Although the subgroup analysis yielded preliminary results, we believe that the conclusions based on GFMF alone are one-sided, and the assessment of CP should be comprehensive. In addition, only 9 literatures were included in this study, which makes the results of combined analysis may be biased. Therefore, highquality RCTs are still necessary in the future to obtain more accurate results.

5 Conclusion

In conclusion, the treatment of stem cells for CP was effective and safe, but the current treatment regimen is still not perfect. We summarize the factors that may influence the outcome of treatment in Figure 8. It is urgent to establish a standardized treatment protocol through a large number of trials, such as the most suitable stem cell type, dose and age of intervention need to be screened. These may lead to the discovery of SCT for CP and its pathogenesis, thus further improving the therapeutic effect. We expect SCT to be used in the clinical treatment of CP and have significant therapeutic effects, nevertheless, rehabilitation training is still essential. SCT improves the patient's pathology, but rehabilitation therapy can accelerate the recovery of the patient's limb function and social skills. In the future, SCT combined with rehabilitation therapy may be a new direction in the treatment of CP.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Author contributions

All authors contributed to the article and approved the submitted version. JQ: Conceptualization, data curation, methodology, software, visualization, writing original draft, and writing review editing. LZ: Data curation, formal analysis, writing original draft, and writing review editing. HZ: Data curation, formal analysis, software, and visualization. DH: Formal analysis, software, and supervision. YL: Methodology, supervision, and visualization. JC: Formal analysis, writing original draft. LL: Data curation, visualization. ZZ: Formal analysis, writing original draft. ZH: Writing original draft, writing review editing. MZ: Conceptualization, supervision. JY: Conceptualization, formal analysis, methodology, project administration, resources; supervision, writing original draft, and writing review editing.

Funding

The authors are grateful for the financial support received from The National Natural Science Foundation of China (Grant No. 32060232), The Jiangxi Provincial Natural Science Foundation (Grant No. 20212BAB206075), The Foundation of Jiangxi Educational Committee (GJJ180791), The Science and Technology Project of Jiangxi Provincial Health Commission (20191079), The Open Project of Key Laboratory of Prevention and treatment of cardiovascular and cerebrovascular diseases, Ministry of Education (XN201913), The Foundation of Technology Innovation Team of Gannan Medical University (TD201806), The Foundation of Technology Innovation Team of First Affiliated Hospital of Gannan Medical University (2021CXTD-08), Key Project Foundation of Gannan Medical University (ZD201831), First Affiliated Hospital of Gannan Medical University, Doctor Start-up Fund (QD076), The Science and Technology Project of Ganzhou (202101034530).

Acknowledgments

We would like to express our gratitude to the research workers of studies that included in this paper, as well as to Peipei Li for her guidance on mapping and Zicai Liu for his suggestions on data processing. Finally, special thanks to Yi Li and Lihua Yang for their help in formal analysis, software and supervision.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

References

Aisen, M. L., Kerkovich, D., Mast, J., Mulroy, S., Wren, T. A., Kay, R. M., et al. (2011). Cerebral palsy: Clinical care and neurological rehabilitation. *Lancet Neurology* 10 (9), 844–852. doi:10.1016/s1474-4422(11)70176-4

Amanat, M., Majmaa, A., Zarrabi, M., Nouri, M., Akbari, M. G., Moaiedi, A. R., et al. (2021). Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: A randomized double-blind sham-controlled clinical trial. *Stem Cell Res. Ther.* 12 (1), 439. doi:10.1186/s13287-021-02513-4

Bax, M., Goldstein, M., Rosenbaum, P., Leviton, A., Paneth, N., Dan, B., et al. (2005). Proposed definition and classification of cerebral palsy, April 2005. *Dev. Med. Child. Neurol.* 47 (8), 571–576. doi:10.1017/s001216220500112x

Bennet, L., Tan, S., Van den Heuij, L., Derrick, M., Groenendaal, F., van Bel, F., et al. (2012). Cell therapy for neonatal hypoxia-ischemia and cerebral palsy. *Ann. Neurol.* 71 (5), 589–600. doi:10.1002/ana.22670

Chamberlain, G., Fox, J., Ashton, B., and Middleton, J. (2007). Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. *Stem cells Dayt. Ohio*) 25 (11), 2739–2749. doi:10.1634/stemcells.2007-0197

Chin, E. M., Gorny, N., Logan, M., and Hoon, A. H. (2022). Cerebral palsy and the placenta: A review of the maternal-placental-fetal origins of cerebral palsy. *Exp. Neurol.* 352, 114021. doi:10.1016/j.expneurol.2022.114021

Colver, A., Fairhurst, C., and Pharoah, P. O. (2014). Cerebral palsy. Lancet 383 (9924), 1240–1249. doi:10.1016/s0140-6736(13)61835-8

Cumpston, M., Li, T., Page, M. J., Chandler, J., Welch, V. A., Higgins, J. P., et al. (2019). Updated guidance for trusted systematic reviews: A new edition of the Cochrane handbook for systematic reviews of interventions. *Cochrane Database Syst. Rev.* 10, Ed000142. doi:10.1002/14651858.ed000142

Eggenberger, S., Boucard, C., Schoeberlein, A., Guzman, R., Limacher, A., Surbek, D., et al. (2019). Stem cell treatment and cerebral palsy: Systemic review and metaanalysis. *World J. Stem Cells* 11 (10), 891–903. doi:10.4252/wjsc.v11.i10.891

El Tantawi, N. T., Abd Elmegid, D. S., and Atef, E. (2019). Seizure outcome and epilepsy patterns in patients with cerebral palsy. *Seizure* 65, 166–171. doi:10.1016/j. seizure.2019.01.003

Greene, A. K. (2021). Cerebral palsy and the data of pain. *Dev. Med. Child. Neurol.* 63 (9), 1012. doi:10.1111/dmcn.14877

Gu, J., Huang, L., Zhang, C., Wang, Y., Zhang, R., Tu, Z., et al. (2020). Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: A randomized, controlled trial. *Stem Cell Res. Ther.* 11 (1), 43. doi:10.1186/s13287-019-1545-x

Heng, B. C., Cowan, C. M., and Basu, S. (2008). Temperature and calcium ions affect aggregation of mesenchymal stem cells in phosphate buffered saline. *Cytotechnology* 58 (2), 69–75. doi:10.1007/s10616-008-9174-8

Hielkema, T., and Hadders-Algra, M. (2016). Motor and cognitive outcome after specific early lesions of the brain - a systematic review. *Dev. Med. Child. Neurol.* 58, 46–52. doi:10.1111/dmcn.13047

Hielkema, T., Hamer, E. G., Ebbers-Dekkers, I., Dirks, T., Maathuis, C. G., Reinders-Messelink, H. A., et al. (2013). GMFM in infancy: Age-specific limitations and adaptations. *Pediatr. Phys. Ther.* 25 (2), 168–176. doi:10.1097/pep.0b013e318288d370

Higgins, J. P., Altman, D. G., Gøtzsche, P. C., Jüni, P., Moher, D., Oxman, A. D., et al. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ Clin. Res. ed)* 343, d5928. doi:10.1136/bmj.d5928

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fbioe.2022. 1006845/full#supplementary-material

Hoare, B., Ditchfield, M., Thorley, M., Wallen, M., Bracken, J., Harvey, A., et al. (2018). Cognition and bimanual performance in children with unilateral cerebral palsy: Protocol for a multicentre, cross-sectional study. *BMC Neurol.* 18 (1), 63. doi:10.1186/s12883-018-1070-z

Huang, L., Zhang, C., Gu, J., Wu, W., Shen, Z., Zhou, X., et al. (2018). A randomized, placebo-controlled trial of human umbilical cord blood mesenchymal stem cell infusion for children with cerebral palsy. *Cell Transpl.* 27 (2), 325–334. doi:10.1177/0963689717729379

Ingram, T. T. (1955). A study of cerebral palsy in the childhood population of Edinburgh. Archives Dis. Child. 30 (150), 85-98. doi:10.1136/adc.30.150.85

Jantzie, L. L., Scafidi, J., and Robinson, S. (2018). Stem cells and cell-based therapies for cerebral palsy: A call for rigor. *Pediatr. Res.* 83 (1-2), 345–355. doi:10. 1038/pr.2017.233

Kang, M., Min, K., Jang, J., Kim, S. C., Kang, M. S., Jang, S. J., et al. (2015). Involvement of immune responses in the efficacy of cord blood cell therapy for cerebral palsy. *Stem cells Dev.* 24 (19), 2259–2268. doi:10.1089/scd.2015.0074

Khandaker, G., Muhit, M., Karim, T., Smithers-Sheedy, H., Novak, I., Jones, C., et al. (2019). Epidemiology of cerebral palsy in Bangladesh: A population-based surveillance study. *Dev. Med. Child. Neurol.* 61 (5), 601–609. doi:10.1111/dmcn.14013

Kiasatdolatabadi, A., Lotfibakhshaiesh, N., Yazdankhah, M., Ebrahimi-Barough, S., Jafarabadi, M., Ai, A., et al. (2017). The role of stem cells in the treatment of cerebral palsy: A review. *Mol. Neurobiol.* 54 (7), 4963–4972. doi:10.1007/s12035-016-0030-0

Kimbrel, E. A., and Lanza, R. (2020). Next-generation stem cells - ushering in a new era of cell-based therapies. *Nat. Rev. Drug Discov.* 19 (7), 463–479. doi:10.1038/s41573-020-0064-x

Kułak-Bejda, A., Kułak, P., Bejda, G., Krajewska-Kułak, E., and Kułak, W. (2016). Stem cells therapy in cerebral palsy: A systematic review. *Brain Dev.* 38 (8), 699–705. doi:10.1016/j.braindev.2016.03.002

Li, Y., Yang, L., Hu, F., Xu, J., Ye, J., Liu, S., et al. (2022). Novel thermosensitive hydrogel promotes spinal cord repair by regulating mitochondrial function. ACS Appl. Mat. Interfaces 14 (22), 25155–25172. doi:10.1021/acsami.2c04341

Little, W. (1861). On the influence of abnormal parturition, difficult labours, premature birth, and asphyxia neonatorum on the mental and physical condition of the child, especially in relation to deformities. *Trans. Obstet. Soc. Lond.* 3, 293.

Liu, X., Fu, X., Dai, G., Wang, X., Zhang, Z., Cheng, H., et al. (2017). Comparative analysis of curative effect of bone marrow mesenchymal stem cell and bone marrow mononuclear cell transplantation for spastic cerebral palsy. *J. Transl. Med.* 15 (1), 48. doi:10.1186/s12967-017-1149-0

Luan, Z., Liu, W., Qu, S., Du, K., He, S., Wang, Z., et al. (2012). Effects of neural progenitor cell transplantation in children with severe cerebral palsy. *Cell Transpl.* 21, S91–S98. doi:10.3727/096368912x633806

Lv, Z-Y., Li, Y., and Liu, J. (2021). Progress in clinical trials of stem cell therapy for cerebral palsy. *Neural Regen. Res.* 16 (7), 1377–1382. doi:10.4103/1673-5374.300979

Maroof, A. M., Keros, S., Tyson, J. A., Ying, S. W., Ganat, Y. M., Merkle, F. T., et al. (2013). Directed differentiation and functional maturation of cortical interneurons from human embryonic stem cells. *Cell stem Cell* 12 (5), 559–572. doi:10.1016/j. stem.2013.04.008

Mei, C., Fern, B., Reilly, S., Hodgson, M., Reddihough, D., Mensah, F., et al. (2020). Communication behaviours of children with cerebral palsy who are minimally verbal. *Child. Care Health Dev.* 46 (5), 617–626. doi:10.1111/cch.12792

Min, K., Song, J., Kang, J. Y., Ko, J., Ryu, J. S., Kang, M. S., et al. (2013). Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: A double-blind, randomized, placebo-controlled trial. *Stem cells Dayt. Ohio)* 31 (3), 581–591. doi:10.1002/stem.1304

Nguyen, L. T., Nguyen, P. H., and Hoang, D. M. (2021). A phase II randomized clinical trial of the safety and efficacy of intravenous umbilical cord blood infusion for treatment of children with autism spectrum disorder. *J. Pediatr.* 230, 271–272. doi:10.1016/j.jpeds.2020.11.063

Novak, I., Hines, M., Goldsmith, S., and Barclay, R. (2012). Clinical prognostic messages from a systematic review on cerebral palsy. *Pediatrics* 130 (5), e1285–e1312. doi:10.1542/peds.2012-0924

Novak, I., Morgan, C., Adde, L., Blackman, J., Boyd, R. N., Brunstrom-Hernandez, J., et al. (2017). Early, accurate diagnosis and early intervention in cerebral palsy: Advances in diagnosis and treatment. *JAMA Pediatr.* 171 (9), 897–907. doi:10.1001/jamapediatrics.2017.1689

Novak, I., Walker, K., Hunt, R. W., Wallace, E. M., Fahey, M., and Badawi, N. (2016). Concise review: Stem cell interventions for people with cerebral palsy: Systematic review with meta-analysis. *Stem Cells Transl. Med.* 5 (8), 1014–1025. doi:10.5966/sctm.2015-0372

Oskoui, M., Coutinho, F., Dykeman, J., Jetté, N., and Pringsheim, T. (2013). An update on the prevalence of cerebral palsy: A systematic review and meta-analysis. *Dev. Med. Child. Neurol.* 55 (6), 509–519. doi:10.1111/dmcn.12080

Peng, X., Song, J., Li, B., Zhu, C., and Wang, X. (2020). Umbilical cord blood stem cell therapy in premature brain injury: Opportunities and challenges. *J. Neurosci. Res.* 98 (5), 815–825. doi:10.1002/jnr.24548

Perets, N., Segal-Gavish, H., Gothelf, Y., Barzilay, R., Barhum, Y., Abramov, N., et al. (2017). Long term beneficial effect of neurotrophic factors-secreting mesenchymal stem cells transplantation in the BTBR mouse model of autism. *Behav. Brain Res.* 331, 254–260. doi:10.1016/j.bbr.2017.03.047

Rah, W-J., Lee, Y-H., Moon, J-H., Jun, H-J., Kang, H-R., Koh, H., et al. (2017). Neuroregenerative potential of intravenous G-CSF and autologous peripheral blood stem cells in children with cerebral palsy: A randomized, double-blind, cross-over study. J. Transl. Med. 15, 16. doi:10.1186/s12967-017-1120-0

Rosenblum, S., Wang, N., Smith, T. N., Pendharkar, A. V., Chua, J. Y., Birk, H., et al. (2012). Timing of intra-arterial neural stem cell transplantation after hypoxia-

ischemia influences cell engraftment, survival, and differentiation. *Stroke* 43 (6), 1624-1631. doi:10.1161/strokeaha.111.637884

Segal-Gavish, H., Karvat, G., Barak, N., Barzilay, R., Ganz, J., Edry, L., et al. (2016). Mesenchymal stem cell transplantation promotes neurogenesis and ameliorates autism related behaviors in BTBR mice. *Autism Res.* 9 (1), 17–32. doi:10.1002/aur. 1530

Shariati, M., Esfahani, R. J., Bidkhori, H. R., Sabouri, E., Mehrzad, S., and Sadr-Nabavi, A. (2021). Cell-based treatment of cerebral palsy: Still a long way ahead. *Curr. stem Cell Res. Ther.* 17 (8). 741–749. doi:10.2174/1574888X16666211102090230

Siniscalco, D., Bradstreet, J. J., Sych, N., and Antonucci, N. (2013). Perspectives on the use of stem cells for autism treatment. *Stem cells Int.* 2013, 1–7. doi:10.1155/2013/262438

Smith, M. J., Paton, M. C. B., Fahey, M. C., Jenkin, G., Miller, S. L., Finch-Edmondson, M., et al. (2021). Neural stem cell treatment for perinatal brain injury: A systematic review and meta-analysis of preclinical studies. *Stem Cells Transl. Med.* 10 (12), 1621–1636. doi:10.1002/sctm.21-0243

Sohni, A., and Verfaillie, C. M. (2013). Mesenchymal stem cells migration homing and tracking. *Stem cells Int.* 2013, 1–8. doi:10.1155/2013/130763

Stadskleiv, K. (2020). Cognitive functioning in children with cerebral palsy. Dev. Med. Child. Neurol. 62 (3), 283–289. doi:10.1111/dmcn.14463

Sun, J. M., Song, A. W., Case, L. E., Mikati, M. A., Gustafson, K. E., Simmons, R., et al. (2017). Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy: A randomized, placebo-controlled trial. *Stem cells Transl. Med.* 6 (12), 2071–2078. doi:10.1002/sctm.17-0102

Tang, Y., Zhou, Y., and Li, H. J. (2021). Advances in mesenchymal stem cell exosomes: A review. *Stem Cell Res. Ther.* 12 (1), 71. doi:10.1186/s13287-021-02138-7

Xie, B., Chen, M., Hu, R., Han, W., and Ding, S. (2020). Therapeutic evidence of human mesenchymal stem cell transplantation for cerebral palsy: A meta-analysis of randomized controlled trials. *Stem cells Int.* 2020, 1–10. doi:10.1155/2020/5701920

Yang, S., Xia, J., Gao, J., and Wang, L. (2021). Increasing prevalence of cerebral palsy among children and adolescents in China 1988-2020: A systematic review and meta-analysis. *J. Rehabil. Med.* 53 (5), jrm00195. doi:10.2340/16501977-2841